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ABSTRACT 
Erythromycin is a macrolide antibiotic with a spectrum similar 
to penicillin and is used mainly in the treatment of infections 
caused by gram-positive organisms. Since its discovery in 1952, 
erythromycin has achieved wide-spread clinical use. 
Susceptibility of erythromycin base to inactivation by acid 
results in decreased availability following exposure to acidic 
gastric fluids. Formulation of acid resistant dosage forms 
and the preparation of acid stable chemical derivatives have been 
attempted to improve absorption and subsequent clinical efficacy . 
Two of the most common ly used erythromyc i n deri vat ives are the 
stearic acid salt (erythromycin stearate) and the lauryl 
sulphate salt of the propionyl ester (erythromycin estolate). 
Although it has been known for many years that erythromycin is 
susceptible to acid degradation, very few reports on the 
stability of erythromycin in aqueous solutions appear in the 
literature. In this study, a high-performance liquid 
chromatographic system using electrochemical detection was 
emp loyed for a kinetic study of erythromycin degradation. The 
effect of varying acid pH on the degradation rate of both 
erythromycin base and erythromycin stearate, and the effect on 
the hydrolysis r ate of erythromyc in estolate is presented. In 
addition, the effect of temperature on erythromycin degradation 
was also investigated. 
xvii 
Unti 1 recently, the majority of pharmacokinetic and 
bioavailability studies have utilized relatively non-specific 
microbiological assay procedures. However, in this study a solid 
phase extract ion, fo 11 owed by the use of a high-performance 
liquid chromatographic system using electrochemical 
coulometric detection was employed for the determination of 
erythromycin in biological fluids. Human volunteers each 
received enteric coated erythromycin base pellets in capsule 
dosage form and also film coated erythromycin stearate tablets 
on separate occasions. 
Results from the clinical trials revealed the enteric coated 
erythromycin base pellets had a greater bioavailability than the 
film coated erythromycin stearate tablets. Computer fitting of 
data revealed no intra-volunteer variabil ity in elimination rate 
constants, suggesting differences in serum levels following 
administration of both dosage forms are due to variation in 
absorption. Results from the clinical trials were also compared 
with those obtained from a further trial, during which the same 
volunteers received erythromycin estolate. 
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CHAPTER 1 
I NTRODUCTI ON 
1.1 DISCOVERY 
Erythromycin was discovered by McGuire et al in 1952 (1). Erythromycin 
is an antibiotic produced by the growth of certain strains of 
Streptomyces erythreus and is a mixture consisting largely of 
erythromycin A with lesser amounts of erythromycin B and erythromycin 
C (2). The struc:ture of erythromycin A and its components appear in 
Fig. 1.1. 
Fig 1.1. . Structure of erythromycin and its components 
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1. 2 PHYSICOCHEMICAL PROPERTIES 
Erythromycin is a po1yhydroxy1actone containing two sugars: L-
c1adinose which contains no nitrogen but one methoxy group and 0-
desosamine which is a 3-N-dimethy1aminodeoxy sugar (3). The 
aglycone part of the molecule is a 14 membered lactone called 
erythrano 1 i de A. Both clad i nose and desosami ne a re bound to the 
lactose ring by a 8 -glycoside linkage (3). 
The biosynthes i s of erythromycin from erythrano 1 ide A 
studied by Hung, Marks and Tardrew (4). The 
biosynthetic pathway appears in Fig 1.2. 
Erythromycin 
soluble in 
is a crystalline, 
water (~2mg/m1) 
acetone, chloroform, acetonitrile 
white compound which is 
but freely soluble in 
and ethyl acetate (5). 
has been 
proposed 
slightly 
a 1coho 1s, 
Erythromycin is a weak base (pKa = 8.6) and is unstable in acidic and 
strongly alkaline solutions, showing its maximum stability between pH 
6 and 9.5 (6). The principle acid degradation products are the 6,9-
hemiketa1 of 8,9-anhydroerythromycin (or enol-ether) and 8,9-
anhydroerythromycin, the structures of which are depicted in Fig 1.3 
(7- 10). The dry powder is stable but should be stored below 300C and 
protected from 1 i ght (6). Aqueous, a 1coho 1 i c so 1 ut ions buffered at 
pH 7-8 are stable for about one week under refrigeration at 40 C (6). 
Erythromycin A, C37H67N013 has a melting point of 1370C-1400C 
and [a~:r= -780C (c = 2% ethanol), whilst the hydrochloride has a 
melting point of 1700C - 1730C (3). 
Fig 1.2 
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Chemical structures of the predominant acid degradation 
products of erythromycin 
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1.3 STABILITY 
Susceptibility of erythromycin to inactivation by acid results in 
decreased absorption following exposure to gastric secretions (11). 
Formulation of acid resistant dosage forms and the preparation 
of acid stable chemical derivatives have attempted to improve 
absorption and subsequent serum levels (12). Modifications 
in the chemical structure of the molecule includes the formation of a 
salt (the stearate), an ester (the ethyl succinate or propionate) 
or the lauryl sulphate salt of the propionyl ester (the estolate). 
The most recent ester reported is erythromycin acistrate (stearic 
acid salt of the 2'-acetyl ester) which has undergone some 
preliminary studies (13). Results from a comparative bioavailability 
5 
study reveal erythromycin acistrate produced higher erythromycin serum 
concentrations than erythromycin stearate. 
Given intramuscularly erythromycin is irritant, although certain 
erythromycin esters 
Preparat ions for 
glucoheptonate and 
have been used as intramuscular preparations. 
intravenous use include erythromycin 
erythromycin lactobionate. The structural 
formulae of the most commonly used erythromycin derivatives are 
depicted in Fig 1.4. 
Fig 1.4 Structural formula of erythromycin and its derivatives 
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1.4 CLINICAL PHARMACOLOGY 
1.4.1 Mode of Action 
Erythromycin penetrates the cell wall of sensitive bacteria (14) and 
attaches to the 50S ribosomal subunit in the presence of ammonium 
or potassium ions (15). Absence of the 50S subunit in the human host 
leads to selective toxicity for the micro-organism. 
A single molecule of erythromycin attaches to each ribosomal 
fragment. In binding to the 50S subunit erythromycin prevents 
translocation, the step in polypeptide chain formation which follows 
elongation, hence inhibiting protein synthesis (15). Erythromycin 
also prevents the incorporation of certain amino acids into 
polypeptide linkages (14). 
Although erythromycin acts to inhibit protein synthesis, it may be 
bacteriostatic or bactericidal depending on the concentration of the 
drug and the sensitivity of the micro-organism (14). 
1. 4.2 Spectrum 
Erythromycin has a spectrum similar to that of penicillin, and is 
active against most gram positive and some gram negative 
organisms. Erythromycin is also active against Treponema 
pa 77idum, members of the rickettsiaceae, as well as Mycoplasma 
pneumoniae, Legione77a pneumophilia, Chlamydia and atypical 
mycobacteria (14, 16). Typical in vitro sensitivities of organisms to 
erythromycin are summarized in Table 1.1. 
7 
Table 1.1 Typical in vitro sensitivities of organisms to 
erythromyci n 
Organism 
S. aureus 
Streptococcus pyogenes 
Streptococcus pneumoniae 
Streptococcus veridans 
Enterococcus 
Clostridium perfringens 
Listeria monocytogenes 
Corynebacterium diphtheriae 
Actinomyces israelii 
Nocardia asteroides 
Neisseria meningitidis 
Neisseria gonorrheae 
Hemophilus influenzae 
Bordate Iia pertuss is 
Bacteroides fragilis 
Brucella species 
Mycoplasma pneumoniae 
Mycobacterium kansasii 
~gent of Legionnaires' disease 
1.4.3. Resistance 
Certain strains of Staphylococcus 
resistant to erythromycin (16). 
Typical Minimum 
Inhibitory Concentration 
(ug/ml) 
Mean 
0.4 
0.04 
0.05 
0.06 
1.5 
0.5 
0.16 
0.02 
0.5 
25 
0.4 
0.1 
3.1 
0.3 
1.5 
5 
0.005 
1 
~0.05 
Range 
0.005->100 
0.005-0.8 
0.006-0.2 
0.02-0.1 
0.1->400 
0.5-5 
0.1-0.3 
0.006-0.2 
0. 2-0.5 
0.2->200 
0.1-0.8 
0.005-0.4 
0.1-6 
0.02-1.56 
0.12->128 
0.3-10 
0.001-0.01 
0.5-2 
aureus have been shown to be 
Some staphylococci resistant to 
8 
erythromycin were found to be res i stant to a 11 macro 1 ide 
antibiotics although the degree of resistance varies from strain to 
strain. Resistance to erythromycin appears to be related to a unique 
plasmid determined mechanism and is caused by the methylation 
of specific sites on the 50S subunit which prevents the binding of 
erythromycin, 
(16). 
a process necessary for antibacterial activity 
Increased resistance is more common following prolonged treatment with 
erythromycin than short term treatment and it is therefore thought 
that erythromyc i n met abo 1 i tes may be respons i b 1 e for induct i on of 
resistance (17). 
1.4.4. Clinical Uses 
The efficiency of erythromycin against so many gram positive cocci 
and against Haemophilus influenza and Mycoplasma pneumoniae makes it an 
excellent respiratory tract antibiotic. 
for streptococcal tonsilopharyngitis, 
Erythromyci n is recommended 
and for other pharyngea 1 
infections, for sinusitis, 
and acute bronchitis as well as 
otitis media, laryngitis, tracheitis 
primary atypical pneumonia (18). 
Erythromycin is the drug of choice for Rheumatic Fever and is also 
effect i ve aga i nst Legiona ires disease, syph il is and gonorrhoea 
(16) . 
For persons allergic to penici 11 in who require an antibacterial 
agent, erythromyci n is the drug of choi ce prov i ded penetrat ion 
across the blood brain barrier is not required, such as in 
bacterial meningitis (15). Erythromycin has also been used in place 
of penicillin to treat enterococcal endocarditis and urinary 
tract infections . 
Although 
treated, 
the dose of erythromycin is dependent 
the usua 1 adu lt dose is 1-4g per 
on the 
day. 
condition being 
Doses should be 
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divided such that a maximum of SOOmg should be ingested as a single 
dose to minimize gastrointestinal intolerance. For children the 
usual dose is 2S-S0mg/kg/day which should be divided so as to be 
administered 2-4 times daily. 
Intravenous administration is reserved to treat severe infections. 
The usual dose is O.S - 1 gram every 6 hours, which may be given for 
as long as 4 weeks, although thrombophlebitis may become a problem 
(19). 
1.4.S. Adverse Drug Reactions 
Erythromycin is regarded as the least toxic of the commonly used 
antibiotics. Side effects are few and in general not serious (16). 
Although mild degrees of epigastric distress, diarrhoea, nausea and 
vomiting are fairly frequently encountered, their severity is 
generally dose related and these symptoms are only rarely serious 
enough to require cessation of therapy. Children are more likely to 
experience nausea and vomiting (19). 
Cutaneous eruptions caused by hypersensitivity have been 
reported , a lthough these cases are rare (16) . Another rare 
complication 
reversible if 
of erythromycin is auditory impairment 
the antibiotic is discontinued (19). 
The most serious toxicity of erythromycin is 
which is 
cholestatic 
hepatitis, which may be caused by various forms of erythromycin. 
A I though it was wi de ly accepted that the esto late deri vat i ve was 
primarily responsible for causing cholestatic jaundice (1S, 20, 21) 
recent evidence suggests that this may not be the case (20). In a 
study using prescription monitoring of 1200 patients receiving 
erythromyc in stear ate and es t o I ate, resu lts suggested that the 
inc i dence of jaund i ce caused by the esto I ate was less than 1 per 
1000 . In the three cases of jaund i ce reported a 11 three pat i ents 
received erythromycin stearate (20). 
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Symptoms of cholestatic hepatitis begin after 10 - 20 days of 
treatment. Clinical characteristics include abdominal pain, 
nausea, and vomiting followed by the development of jaundice, 
acholic stools, dark urine and hepatomegaly. Patients recover 
rapidly after erythromycin treatment is discontinued. 
Thrombophlebitis occurs relatively frequently with intravenous 
administration of erythromycin (16), although the lactobionate salt 
of erythromycin may be less irritating (22). Erythromycin should not 
be given intramuscularly since it causes severe local pain. 
1.4.6. Drug Administration 
Erythromycin in therapeutic doses has been shown to chiefly 
influence the hepatic elimination of several drugs, which might well 
be prescribed concomitantly with the antibiotic (18). Evidence 
suggests that erythromycin interacts with theophylline, carbamazepine, 
warfarin and phenytoin. It has been suggested that erythromycin 
reduces the capac ity of the mixed funct i on ox i dase system in the 
1 iver. 
Extensive studies on the interaction of erythromycin and 
theophylline have been carried out. Some reports show that 
concomitant administration of erythromycin and theophylline leads to a 
significant elevation of serum theophyll ine levels although other 
reports show no interactions (23, 24). The mechanism of interference 
by erythromycin with theophylline disposition is unclear although 
it may possibly be explained in 
of the I-demethylation pathway 
demethylated (24). Clinically it is 
the theophylline dose may 
erythromycin treatment (24). 
part, by competitive inhibition 
by erythromycin which is itself 
suggested that a reduction in 
be desirable during concomitant 
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Wong et a 1 (25) reported that although there were no differences in 
apparent volume of distribution, elimination rate constant or 
absorption rates, the clearance of a single oral dose of 
carbamazepine was reduced in the presence of erythromycin. 
Further studies are indicated since this study was based on a 
single carbamazepine dosage which does not mimic the clinical 
situation (25). 
After three days of concomitant warfarin and erythromycin 
therapy, erythromycin was shown to increase the prothrombin time of a 
warfarin stabilized patient by 40% (26). 
A study of clearance of a single dose of 
erythromycin treatment reported that even though 
phenytoin during 
erythromycin failed 
to significantly decrease mean phenytoin clearance, some individual 
subjects exhibited pronounced decreases in phenytoin clearance, 
providing sufficient incentive to closely monitor patients taking 
both drugs (27). 
1.5. PHARMACOKINETICS 
1.5.1 Bioavailability Data 
Erythromycin · stearate which dissociates in the intestinal tract and 
erythromycin base are absorbed as the free base (28). The lauryl 
sulphate salt moeity of the estolate, however, dissociates in the 
intestinal tract and is absorbed as the propionyl ester which must 
subsequently be hydrolyzed in vivo to the active base form. Similarly 
the ethyl succinate must also be hydrolysed in vivo to the bioactive 
free base (2). 
Until recently, the assay of serum erythromycin has been carried out 
microbiologically (29). Microbiological assays, which are based on 
comparison of the dose which inhibits growth of a suitable micro-
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organism with the dose of the standard preparation which produces 
the same degree of inhibition, do not distinguish between active 
parent drug, the unhydrolysed form or metabolites. 
It has been shown that erythromycin estolate produces a higher total 
blood level than other erythromycin derivatives but studies have shown 
that on ly a sma 11 port i on of the esto 1 ate is hydro lysed to 
the active drug in the blood (30). Therefore, although the 
estolate 
absorption, 
therapeutic 
shows greater 
this may not 
efficiency. 
efficiency 
necessari ly 
The rapid in vitro hydrolysis of 
of gastrointestinal 
be i nd i cat i ve of higher 
the estolate during 
microbiological assay procedures has led to an overestimation of 
biologically active drug in the patient. The estolate also shows a 
higher degree of protein binding than the free base (31, 32). 
Although a vast amount of bioavailability data has been reported in 
the literature, comparison of bioavailability data between studies 
is difficult due to differences in study protocols and analytical 
techniques. Various suggestions regarding protocols and 
interpretation of results have been reported (12, 33-37) . It must be 
noted , however, that the results of comparative bioavailability 
studies involving erythromycin and its derivatives are only 
valid for products evaluated under the same conditions (33, 38). 
1.5.2 Absorption 
Erythromycin base is very unstable in acid (11). This has led to the 
formulation of enteric coated dosage forms to protect the base from 
acid degradation in the stomach. Coating is reported to decrease the 
acid degradation and also cause a sl ight delay in absorption (11, 
39-41). The absorption of erythromycin from two different enteric 
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coated preparations, enteric coated tablets and enteric coated pellets 
has been eva 1 uated. The enteri c coated pe llets led to a higher, more 
regular absorption of erythromycin than did coated tablets (42). 
The absorpt i on of erythromyc i n base has been reported 
reduced, delayed or not affected by the presence 
depending on the formulation or dosage regimen used (43). 
to be 
of food 
Smith et aT reported fasting subjects absorbed well, but if the dose 
was taken after food, absorption was reduced (44). The absorption 
of erythromycin base by patients with achlorhydria was not affected by 
food, although the absorption was slower and peak serum levels occurred 
later (44). 
Erythromycin stearate bioavailability is reported to be sensitive to 
the presence of food . Reduced bioavailability of erythromycin stearate 
in the presence of food has been confirmed in single and multiple dose 
studies (7, 45-47). In a study (46) comparing erythromycin base and 
erythromyc i n stearate bioava i 1 ab i 1 i ty, the mean peak erythromycin 
concentrations following a single oral 500mg dose of erythromycin 
base were 1.84 .±. 1.15 pg/ml and 1.91 .±. 1.57 pg/ml when the dose was 
taken before and after breakfast, respectively. Erythromycin 
stearate taken before and after breakfast was reported to 
have mean peak erythromycin concentrations of 2.09 + 1.06 
pg/ml and 0.37 .±. 0.40 pg/ml respectively, suggesting erythromycin 
stearate absorption is affected by the presence of food. 
The serum 1 eve 1 s of erythromyc in obta i ned were not on ly affected by 
the presence of food, but were also reduced significantly in 
individuals when the accompanying water was reduced from 250ml to 20ml 
(7). Possible explanations are that stomach emptying is faster 
following the ingestion of a larger volume of water, reducing acid 
degradation. 
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Reduced bioavailability of erythromycin stearate given together with 
food is possibly due to the increased degradation by gastric acid, 
since the production of acid is increased by food ingestion. 
Although most reports indicate erythromycin stearate bioavailability is 
reduced in the presence of food, Clayton and Leslie (48) concluded 
that erythromycin stearate had a greater bioavailability when 
administered immediately before food. A further study in non-
fasting subjects reported that the peak plasma erythromycin 
concentration following a 500mg oral dose of erythromycin stearate was 
reached more rapidly and was twice as high as that observed in 
fasting subjects. Possibly the food neutralizes and dilutes the 
acid and in addition, gastric motility may aid dispersion and 
result in rapid absorption and enhanced bioavailability (35). 
In 1964, a single and multiple dose study comparing erythromycin 
stearate and erythromycin estolate bioavailability was carried out 
(40). Using a microbiological assay technique, estolate blood 
levels were reported to be at least twice as high as stearate levels 
in the fasting state and more than ten times higher in the non-fast i ng 
state. 
Recent 1 y, however, with the deve lopment of assays wh i ch 
discriminate between the bioactive and bio-inactive portion in the 
plasma, the active erythromycin base has been measured. Using 
discriminatory assay techniques, a single dose of erythromycin 
estolate gave rise to higher plasma levels of total antibiotic than 
the equivalent dose of erythromycin stearate, although the estolate 
produced lower, if somewhat more consistent levels of f ree base (28 , 
47, 50) . 
In a multiple dose study of erythromycin estolate, 
stearate and enter i c coated erythromycin base, it was 
the area under the curve values derived from 
erythromycin 
concluded that 
the free 
er ythromyc i n base concentrations following the admin i strat i on of the 
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three products was not statistically significant (28). 
Erythromycin estolate absorption is reported to be unaffected by the 
presence of food (47, 51, 52) although it has also been reported 
that food may enhance absorption (47, 52). 
1.5.3. Absorption Kinetics 
Numerous studies have been carried out to examine erythromycin 
pharmacokinetics following intravenous administration as well as 
single and multiple oral dosage regimens. 
A zero order absorption model was found to adequately describe the 
pharmacokinet ics following a single dose (47, 53) and a multiple 
dosage regimen (54) . However, first order absorption has been 
suggested following multiple dosing (47, 55, 56) . A further study 
concluded that erythromycin is absorbed at a constant rate in 
some subjects, whereas other subjects followed first order absorption 
rates (51), or a combination of zero order and first order processes 
(58). 
In many studies, acceptable curve fitting was only possible with the 
inclusion of an absorption lag time parameter, (II, 47, 53, 57, 59). 
However, following the administration of a suspension, absorption was 
not delayed . 
Typical pharmacokinetic parameters obtained following oral 
administration of erythromycin base and erythromycin stearate 
appear in Table 1.2. 
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Table 1.2 Typical pharmacokinetic parameters describing 
erythromycin disposition in relation to oral dose 
Dose (mg Base) 
Serum 250 500 1000 500 stearate 
n 20 22 21 22 
lag (hrl 1/4(0/3) 1/4(0/3) 1/3( 0/4) 1/1(0/4) ka (hr- ) 3,2(1,3) 4,3(2,2) 3/2( 1/8) 2/3(0/7) 
Ke fhr- 1) 0/8(0/3) 0/5(0/1) 0/4( 0/1) 0/6(0/2) 
AUC (mg/L/hr) 4/5(1,7) 11/2(4,3) 27,2(10/6) 7,5(3,4) 
AUC2 (mJ/L/hr) 5/4(3/4) 13/2(4,1) 28,6(11 /2) 8/0(3/6) 
T1/2 (hr 2/0(2/0) 2,5(1/0) 3/0( 1/7) 2,7(2/3) 
Standard deviation in parenthesis 
Key n = number of people in trial 
lag = lag period between administration of dose and 
commencement of absorption 
Ka = absorption rate constant 
Ke = elimination rate constant 
AUC.1 = area under the serum concentration-time curve 
AUC .. 2 
calculated by the trapezoidal file 
= AUC calculated with AUTOAN2/NONLIN program 
Reproduced from Josefsson et al (80). 
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1.5 . 4. Distribution 
Erythromycin is widely distributed in the tissues (39). Diffusion into 
the spinal fluid is poor even in the presence of meningial 
inflammation (19). Moderate levels of erythromycin appear in 
tonsil tissue, and pleural fluid and bronchial secretions contain 
erythromyc i n in amounts exceed ing serum 1 eve 1 s (60). Erythromyc i n is 
one of the few antibiotics which penetrate the prostatic fluid (61), 
and anima 1 stud i es revea 1 good penetrat i on into the aqueous humour 
(62). Placental transfer produces low, variable erythromycin 
levels in foetal blood, although it is concentrated in the foetal 
liver (63). 
1.5.5. Binding 
The extent of protein binding is influenced by both drug 
concentrat ion and a 1 bumi n concentrat ion. Different va 1 ues for 
protein binding have been reported although most reports state that 
erythromycin is highly protein bound (13, 13, 32, 64). Prandota 
et aT (64) reported erythromycin to be 73% protein bound whilst 
Wi egund and Chun (31) demonstrated erythromyci n to be 90% bound to 
serum proteins. 
Erythromycin binds to serum albumin but exhibits a high affinity (at 
least 50% bound) for a -acid glycoproteins (64). Since this binding 
is loose and reversible, this does not appear to influence 
erythromycin tissue levels (18, 40). 
1.5.6 Metabolism 
A considerable amount of erythromycin is metabolised in the liver (39) . 
Erythromyc i n is reported to be rap i d 1 Y demethy 1 a ted i n the 1 i ver to 
yield des-N-methylerythromycin. A study carried out on rats (65), 
dogs (66) and rabbits (67) demonstrated that a metabo 1 ite 
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excreted in the bile was identical to des-N-methylerythromycin . A 
further study on the met abo 1 i sm of erythromycin in rats conc 1 uded 
that des-N-methyl erythromycin is the only microbiologically active 
metabolite, and was excreted in the bile and passed out in the faeces. 
A recent study, (68) has concluded that repeated doses of 
erythromycin may actually induce increased metabolism by 
increasing both the titre and activity of the enzymes. 
1.5.7 Elimination 
Erythromycin is 
Although highly 
excreted in the urine and the bile (39) . 
variable urine concentrations 
drug is only minimally excreted by this route. 
excreted 
patients 
in the urine varies from 0 . 02% - 15% (63, 
show slightly higher drug excretion in 
are achieved, the 
The portion of dose 
69, 70). Jaundiced 
urine than the non-
jaundiced patients. Alkalinisation of the urine was reported to have 
no effect on the urinary concentration of erythromycin or the 
total daily urinary excretion although it does increase the 
antibacterial activity of erythromycin present in the urine (71). 
Erythromycin excretion is not significantly affected by urine 
a 1 ka 1 i nat i on suggest i ng that act i ve transport processes may be 
involved. This is in agreement with the findings that renal 
clearance of erythromycin is only about 13% of creatinine clearance, 
indicating either an active transport system and/or net tubular re-
absorption of erythromycin. However, Lee et aT (66) investigating the 
rena 1 clearance of erythromyci n in dogs, found that erythromyc i n 
clearance was about 70% of creatinine clearance. Since only a 
small portion of drug is el iminated by the kidneys, the 
elimination rate is not significantly influenced by altered renal 
function. There is, therefore, no need to alter the dosage regimens 
in persons with impaired renal function (72) . However, 
recently reported incidences of reversible hearing loss involving 
patients with renal failure during chronic intravenous therapy, 
indicates further study is necessary (72). 
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B i 1 i ary excret i on is reported as the rna in excret i on pathway of 
erythromycin and des-N-methylerythromycin which are excreted in high 
concentrat ions fo 11 owi ng both ora 1 and intravenous dosages (22, 73, 
74). The concentration of active drug in the bile often exceeds serum 
concentrations suggesting an active secretory process (75). 
1.5.8 Elimination Kinetics 
The pharmacokinetics of distribution and elimination have not been 
adequately characterized. All intravenous studies reported that the 
elimination profiles were consistent with a two compartment 
open model with elimination occurring from the central 
compartment (43, 58, 72, 76, 77) . A lthough a two compartment 
open model has been used to characterize the el imination 
profile following a single oral dose (53), one compartment model 
elimination following both single and multiple dosing regimens has also 
been reported (47, 55, 56, 77-79). 
An extensive kinetic study using intravenous (58) and oral dosage 
regimens (57) evaluated elimination profiles using two 
compartment and one compartment mode 1 s, respect ive ly. Th i s study 
concluded that the large subject variability in erythromycin serum 
concentration profiles after oral administration was related to 
variability in absorption kinetics and absolute bioavailability 
rather than variability in disposition kinetics. 
Multiple dosage regimens show that the bioavailability of the 
in it i a 1 dose was lower than subsequent doses (47, 53, 54, 56) In 
addit ion, following a multiple dosage regimen of 250mg oral 
erythromyc i n every 6 hour s, Co lburn et a 1 (54) repor ted the 
average elimination 
higher than day three. 
rate constant on day one was cons i derab ly 
The average halflife increased from 1.8 hours 
on day one to 2.5 hours on day three, suggesting a degree of 
saturation of the ·enzymatic pathways following repeated dosing. 
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Non- 1 i near k i net i cs have been suggested fo llowing both 
intravenous (58) and oral (80) regimens. Increasing the Lv. 
dosage led to a decrease in the elimination rate constant and an 
increase in the volume of distribution and the fraction eliminated in 
the urine (58). Following oral administration, Josefsson et al 
reported a superproportionate increase in the area under the serum 
concentration-t ime curve (AUC) with increas ing dosages indicat ing 
possible dose dependent kinetics. A trend towards an increase in 
the fraction of erythromycin in the urine was also observed. 
Severa 1 papers have reported the poss ibi 1 ity of enterohepatic 
recycling (53, 55, 57, 58, 80, 81). This phenomena manifests in the 
form of irregularities or secondary peaks in the serum 
concentration-time curve following both oral and intravenous 
dosing (55, 80, 82, 83). It has been suggested that these 
irregularities may be linked to food intake (58) although further 
investigation is necessary. 
Typical pharmacokinetic parameters describing erythromycin 
disposition following the Lv . administration of erythromycin 
lactobionate (250mg base equivalent) are given in Table 1.3. 
1.6 STUDY OBJECTIVE 
A lthough it has been known for many years that erythromycin is 
susceptible to acid degradation very few reports on the kinetics of 
the degradation have appeared in the literature. The main objective 
of this study was to investigate the kinetics of erythromycin 
base degradation. A comparative study between the chemical kinetics 
of erythromycin base and erythromycin stearate acid degradation was 
investigated. A brief investigation into erythromycin estolate 
hydrolysis was undertaken . 
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In addition a study using human volunteers was carried out to 
compare the bioavailability and pharmacokinetics following a 
single oral dose of erythromycin base and erythromycin stearate. 
Table 1.3 
n 
Vdss 
Tl a (hr) /2 
Tl/~(hr) 
Cls(l/hr) 
Cl r (L/hr) 
fU 
Typical pharmacokinetic parameters describing 
erythromycin disposition following administration 
of erythromycin lactobionate (250mg base 
equivalent). 
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44,4(11,4) 
0,11(0,07) 
1,5(0,3) 
26,3(7,5) 
3,4(2,4) 
0,12(0,07) 
Standard deviation in parenthesis 
Key n = number of people in trial 
Vdss = apparent volume of distribution at steady state 
equilibrium 
T 1/2 a = distribution half life 
Tl/2 J3 = elimination half life 
Cl s = total body clearance 
Cl r = renal clearance 
fu = fraction of dose excreted unchanged in urine 
Reproduced from Austin et al (58). 
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CHAPTER 2 
DEVELOPMENT OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR THE 
ANALYSIS OF ERYTHROMYCIN AND ITS ACID DEGRADATION PRODUCTS 
2.1 INTRODUCTION 
High performance 1 i qui d chromatography (HPLC) 
analytical technique. Due to its relative 
efficiency, selectivity, 
popularity for use in the 
speed and preclslon, 
analysis of drugs (84-86). 
is a widely used 
simplicity, high 
HPLC has found 
L ike all chromatographic techniques, separation of components in a 
mixture depends on the relative affinities of the various solute 
molecules for the stationary and mobile phase (87). The earliest 
stationary phases of silica were more polar than the mobile phases 
used, resu It i ng in the retent i on of po 1 ar so lutes. More recent ly, 
systems employing a non-polar stationary phase and a more polar mobile 
phase have been developed. This technique referred to as reversed-
phase liquid chromatography (RPC), uses a stationary phase prepared 
by cova lent bond i ng of vari ous hydrocarbons e. g. octyl C8 or 
octadecyl C18 to a silica support. The mobile phase usually consists of 
a mixture of water and water miscible polar organic solvents (84, 88). 
Duri ng preparat ion of the bonded phase a sign ifi cant fract ion of 
surface s il ano 1 s are unreacted with the long chain stat ionary 
phase. Reacting the packing materia 1 with trimethylch loros ilane, a 
process called end-capping, to reduce the number of free silanols 
produces co 1 umns of superior batch to batch un iformity, improved 
column life and reduced peak tailing (89, 90). 
The separat i on of compounds as they move through the co 1 umn can be 
seen to be dependent on three factors; retention, column 
selectivity and column efficiency (91). 
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Once a column is chosen, it is necessary to adjust the eluent 
strength so that the retention times for the peaks of interest are 
in the range of K' values between 1 and 10 (89), where K' is the 
capacity factor and is calculated from Equation 2.1 (see 
Fig. 2.1) 
K' = tr - t m Equation 2. 1 
tm 
Where tm = the time for solvent molecules to traverse the 
column 
tr = the retention time for the compound of interest . 
Large K' values indicate long retention times, which results in 
diffuse bands that are difficult to detect (84 , 91) . 
Fig 2.1 Schematic diagram of a chromatogram 
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Column selectivity, Ct is the ratio of the capacity factors K 1', 
and K2' of two compounds 1 and 2, (Equation 2.2) and is a function of 
the stationary phase properties and the mobile phase eluting power 
(84, 89). 
Ct = K ' 2 
K ' 1 
Column efficiency 
calculated from the 
Equation 2.3 (92). 
or resolving 
plate number, 
N = 2 5.54 tr 
W 
Where tr = peak retention 
Equation 2. 2 
power of the co 1 umn can be 
N. The value is calculated from 
Equation 2.3 
W = peak width at half the peak height. 
Both these values are measured in the same terms of time or 
distance. 
In comparing column efficiencies a more useful parameter is the 
height equivalent to a theoretical plate (HETP). The HETP is 
obtained by dividing N by the length of the column, L. The 
sma ller the HETP, the smaller the zone width and the greater the 
column efficiency (84). 
Column efficiency depends not only on the size and quality of the 
packing material but also on the column packing technique (89). High 
quality stationary phase packing material is commercially available. 
Wet packing, a widely used method of column packing involves the 
pumping of a slurry of column packing material into the column by a 
suitable displacement fluid at high pressure. The main variables 
in slurry packing are the density and viscosity of the solvent 
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and the flow rate and pressure of the slurry (84). Although 
various slurry solvents have been used, carbon tetrachloride has 
been shown to produce high efficiency columns (93, 94). 
Following column selection it is necessary to optimize the mobile phase 
compos it ion unt il adequate separat ion is ach ieved. Se lect ion 
of mobile phase depends on numerous factors including viscosity, 
polarity, compressibility, vapour pressure as well as compatibility 
with the stationary phase and detector (84, 88) . Typical mobile 
.phases used in RPC are mixtures of water (or aqueous buffer) and 
one or more organic solvents (84) . The most widely used organic 
solvents include methanol, acetonitrile and tetrahydrofuran (84). 
Given a choice between solvents of similar polarity, the less viscous 
solvent is chosen since it results in lower pressures and hence extends 
the life of the column (89). 
Modification of accessible silanol groups on the stationary phase by 
the use of buffer salts such as phosphate and citrate leads to reduced 
peak tailing and improved resolution (89, 95) . In addition, pH 
control with the use of buffers can significantly affect the 
retention time of easily ionizable species. For silica based 
bonded materials the useful pH range is 2-8. At pH less than 2, the 
silica-carbon bond is attacked and at high pH values the sil i ca 
substrate dissolves (96). Prior saturation of the mobile phase with 
silica from a silica saturating pre-column may extend the life of the 
analytical column whi 1st working at these extreme pH ranges (97). 
Dissolved gases in the mobile phase can affect detector performance 
and should therefore be controlled (98). This may be achieved by 
the use of an in-line vacuum degassing unit or by the constant purging 
of the mobile phase with helium (89) . 
A large number of detectors have been described for use in 1 iquid 
chromatography (99, 100). The most widely used detectors, due to ease 
of operation, versat il ity and sensitivity are 
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spectrophotometric detectors based on the absorption of ultra-violet 
light (84, 96). Although not universal in application a great many 
substances do absorb ultraviolet radiation. 
Electrochemical methods of detect i on probab ly offer the most 
promi sing 
offering 
approach to developing a universal detector for 
the benefits of both high sensitivity and selectivity 
HPLC, 
(84). 
Since the initial use of electrochemical detection for monitoring 
catecho 1 ami nes in bra i n tissue (101). the use of e 1 ectrochemi ca 1 
detection has grown rapidly . 
Electrochemical detection results from a 
reaction at the surface of the electrode (102). 
current-producing 
This can either be 
an oxidation or reduction reaction. The success with which liquid 
chromatography with electrochemical detection methods can be applied 
is determined by the electrode potential required to affect oxidation 
or reduction of the compound of interest. 
Most detectors limit mobile phase composition to some degree. 
However, electrochemical detectors require the mobile phase to be able 
to carry an ionic current, be electrochemically inert in the desired 
potential range and dissolve the analyte of interest (102). 
Direct electrochemical detection is therefore not likely to be useful 
in normal phase chromotography, since nonpolar organic solvents, 
due to their inability to support a significant ionic strength 
are not we 11 su i ted to e lectrochemi ca 1 react ions. A lternat i ve ly, 
reverse phase chromatographic systems using aqueous mobile phase, with 
or wi thout organ i c mod ifiers are idea 1 for e lectrochemi ca 1 detect i on 
(102, 103). 
Two different approaches can be used for detection of 
e lectroact i ve spec i es, name ly; amperometry and cou lometry. 
Amperometric detectors operate in the limit where the 
concentration of analyte entering and leaving the cell is the same 
(convers i on eff i c iency is zero). Cou lometri c detectors are those 
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where the concentration of entering analyte is reduced to zero as it 
exits the cell (conversion efficiency is 100%). For practical 
purposes amperometric detectors may involve conversion efficiency up to 
5% and coulometric detectors above 95% (103). 
Although many cell designs for solid working electrode detectors have 
been dev i sed, there are bas i ca llY two des i gns in use, name ly; 
the wall jet and the thin layer configuration (103). 
The wall jet principle is based on the impinging of the analyte on 
the head of the working electrode, where the reaction takes place 
(104). A detector based on the wall jet principle appears in Fig 2.2. 
Fig 2.2 Single electrode, amperometric electrochemical detector 
flow cell (Metrohm) 
WORKING ELECTRODE (WE) 
_~.I§~==::::;-:l ="\. I I ~~-.-.., 1>-iiW,£- .IEl--..r---"4-~~ ...J j-J- .J --~===- ~~ 1/1 L.----r 
REFERENCE ELECTRODE (RE) AUXILARY ELECTRODE CAE) 
INLET Eluent 
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The electric current generated by the reaction at the working electrode 
(WE), which is proportional to the amount of eluent, is measured by the 
auxi lary electrode (AE). while the reference electrode (RE) together 
with the electronic potentiostat ensures a constant polarizing 
voltage. All cells operating in this manner are amperometric. 
The type of material used for the RE and AE is not 
choice of WE material is important in affecting 
The most widely used WE materials include carbon 
carbon (105). 
critical but the 
detect i on (102). 
paste and glassy 
Coulometric electrodes are most commonly made of porous graphite or 
carbon composites with inert plastics through which the eluent flows, 
although glassy carbon and carbon paste beds have been used (106). 
The larger area of the working electrode is required in order to obtain 
complete electrolysis (103). Although only a single electrode is 
necessary for detect ion, an innovat ive approach to 
e lectrochemi ca 1 detect i on invo 1 ves the use of two work i ng 
electrodes operated simultaneously at different potentials 
(107-109) (Fig 2 . 3) . The upstream electrode is used as a screening 
electrode. In this operation mode, the upstream electrode is 
he 1 d at an electrode potent i a 1 s 1 i ght ly lower than the downstream 
potent i a 1. The upstream electrode wi 11 therefore comp lete ly oxi d i ze 
and make undetectable other 
than that of the ana lyte. 
at optimum potential for 
species oxidizable at potentials lower 
The downstream electrode can be set 
detecting the analytes (106, 108). 
In addition, when operating potentials are high, a guard cell can be 
incorporated into the HPLC system between the so l vent delivery system 
and injector (106) . This cell consists of a single electrode 
which e l ectrolyses contaminants in the mobile phase prior to 
chromatogr aphy (106) . Th i s ce 11 ensures the mobile phase is 
electrochemically pure since solvents currently available are optically 
pure but not electrochemical ly pur e . 
Fig 2.3 
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Dual electrode, coulometric electrochemical detector 
flow cell (Coulochem) 
UPSTREAM ELECTRODE DOWNSTREAM ELECTRODE 
INLET -7 
. , 
. . 
. - . . '. 
-7 OUTLET 
Cho i ce of opt imum potent i a 1 for ana lyte detect i on is made from a 
vo ltammogram. Th i sis a plot of potent i a 1 app 1 ied versus current 
generated (106) . Two types of vo 1 tammograms can be generated, 
name ly, cyc 1 i c and hydrodynami c vo ltammograms. Cyc 1 i c 
voltammograms have the difficulty of requiring analyte to be 
suppl ied continuosly for a period of 2-4 minutes whi le the 
potential of the electrode is continuosly changed. Although it takes 
longer to acquire the data, this problem is overcome by producing a 
hydrodynami c vo ltammogram. The app 1 ied potent i ali s vari ed and 
allowed to stabilize. At each applied potential an equivalent amount 
of analyte is injected into the system. A plot of applied potential 
versus peak height or area can be constructed. The electrode 
potential which results i n half of the maximum oxidation is called 
the ha lf -wave potent i a 1 and is used to compare the potent i a 1 s at 
which different compounds are oxidized (102, 106). 
The potential selected should be lowest potential at which the 
required 
obtained 
sensitivity is achieved. Greater sens it ivity can 
in th i s manner, s i nce background currents from 
be 
the 
30 
electrodes and so 1 vents increase with increas ing applied 
potential (102, 109). 
2.2 METHODS AVAILABLE 
Numerous methods for the separation and quantitation of 
erythromycin and its degradation products have been reported. 
Paper chromatographic (110) and thin layer chromatographic (111-113) 
methods are available for the separation of erythromycins. However 
these methods are not suitable for precise quantitative analysis. A 
gas chromatographic method capable of separating and quantifying 
erythromycin and degradation products is available . However, this 
method has not found wide-spread use possibly due to the required 
lengthy derivatization (24 hours) of samples (2). 
Several HPLC methods have been reported for raw material, dosage 
form and biological fluid analysis of erythromycin (10, 34, 114-121). 
The first reported HPLC method showed separation of erythromycin A and 
erythromyci n B. However, thi s report fa iled to present quant itat i ve 
data or demonstrate separation of degradation products (144). A novel 
HPLC method based on f1 uorometri c detect i on reported by Tsuj i (115) 
capab 1 e of separat i ng erythromyc in and degradation products has 
apparent 1y not recei ved wi de use, probab 1y due to the 
instrumentation involved and the complexity of the procedure. 
Suitable methods for the quantitative analysis of erythromycin using 
UV detection have been developed (10 . 115-117, 119-121). Using a 
pBondapak C18 reverse phase column with UV detection at 215nm, Tsuji 
et a 7 was able to separate and detect erythromycin and degradation 
products (117). Similarly, Stubbs (119), used UV detection at 200nm. 
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Atkins et al however, used a Lichrosorb RP-8 Sum column with UV 
detection at 214nm to carry out an acid degradation study (16). 
The separation of erythromycin and degradation products has also 
been shown using poly(styrene-divinylbenzene) packing material 
(122) . 
More recently however, HPLC with electrochemical detection has been 
used. Using a C18 column and a dual electrochemical detector in 
the oxidative screen mode, Chen and Chiou (34) reported a simple and 
sensitive method capable of quantitatively measuring erythromycin 
and degradat i on products. The app 1 i ed ce 11 potent i a 1 of the 
screen electrode was set at 0.70V and the sample electrode at 0.90V. 
A further method on the use of electrochemical detection described 
the use of a dual electrode coulometric detector in the oxidative 
mode with the screen potential set at 0.70V and the sample 
electrode set at 0.80V (123). Alternatively, the amperometric 
response given by a glassy carbon electrode can also be used to detect 
erythromycin. However, the detector rapidly loses sens itivity (123) . 
Stubbs (119) reported the use of amperometri c and cou 1 ometr i c 
detectors for the quantitative analysis of erythromycin. Croteau 
(124) recently described an HPLC method using a Novapack end-capped 
C18 co 1 umn with amperometri c detect i on for quant itat i ve 
ana lys i s of erythromyc in base and propi onate. However, a rapi d 
decrease in detector sensitivity (up to 60% in 24 hours) was reported. 
HPLC was chosen for this study because of its inherent advantages over 
other analytical methods . The application of ultraviolet and 
electrochemical amperometric and coulometric detection methods was 
investigated . 
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2.3 MATERIALS AND APPARATUS 
2.3.1. Materials 
Drug samples used: 
Erythromycin Base USP (1) 
Erythromycin Base LOT 85F0251 (2) 
Erythromycin Esto1ate USP (1 ) 
Erythromycin Stearate LOT-07-616-CD (3) 
Erythromycin Eno 1- Ether LOT 3511-55A (3) 
Anhydroerythromycin (3) see Section 
Des-N-methy1erythromycin 
Oleandomycin phosphate 
LOT 164-171- 185-2 
LOT 206/76 7003 
(1) USP Reference Standards, Rockville, USA 
(2) Sigma Chemical Company, St Louis, USA 
(3) Abbott Laboratories, North Chicago, USA 
(4) Lilly Laboratories, Indianpolis, USA 
2.4.3 
(4) 
(5) 
(5) Pfizer Laboratories, Pietermaritzburg, South Africa 
A 11 reagents were of at 1 east ana lyt i ca 1 grade 
Hydrochloric acid and sodium hydroxide were obtained 
quality. 
from BDH 
Chemicals, Poole, England, wh i le phosphoric acid was obtained from 
Carlo Erba, Milan, Italy. 
The acetonitrile used in th i s study was distilled-in-g1ass grade and 
purchased from Burdi ck and Jackson Laboratori es, Muskegon, Mi ch . , 
USA. 
HPLC-grade water was prepared by reverse osmos i s 
followed by passage through a Milli-Q (Mi11ipore Corp . , 
USA) system. 
purification 
Bedford, Mass, 
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2.3 . 2 High-Performance Liguid Chromatographic System 
The HPLC system employed was as follows: 
Model 6000A liquid chromatographic pump (Waters Associates, Milford, 
Mass., USA) 
Mode 1 7108 WISP automated samp 1 e injector (Waters Assoc iates, 
Milford, Mass., USA) 
Column - (see Section 2.4.4) 
Detector - (see Section 2.4.6) 
Model 561 strip-chart recorder (Perkin-Elmer Corp., 
Conn., USA) 
2.3.3 Additional Eguipment 
The following were employed throughout the study: 
Norwalk, 
Type 2004 MP6 five-figure precision balance (Sartorius GmbH, 
Gottingen, W. Germany) 
Model 8845-30 ultrasonic cleaner (Cole-Parmer Instrument Co. , 
Chicago, Ill., USA) 
Model 601 digital ionalyser (Orion Research Incorp, 
Mass., USA) 
Cambridge, 
Model M-16710-12 'maxi-mix' vortex mixer (Thermolyne Corp., 
Dubuque, Iowa, USA) 
Model HN-SII general purpose centrifuge (International Equipment Co., 
Needham Heights Mass., USA) 
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Model MFC BAS microfiltration centrifuge (Bioanalytical Systems Inc., 
W. Lafayette, USA) 
Model SVC-100H Speed Vac Concentrator (Savant) (Savant Instruments 
Inc., Hicksville, New York, USA) 
Model 10302 Vacuum pump (Lammert, Addison, Ill, USA) 
Model A-25 Eyela aspirator (Tokyo Rikakikai Co. Ltd. Tokyo, Japan) 
Model 3521 reciprocating mechanical shaker (Lab-line Instruments Inc., 
Melrose Park, Ill., USA) 
Fixed and variable volume Transferpettes (Brand, W. Germany) 
Magnetic stirrer (GallenKamp, England) 
Column packer (HPLC Technology, Runcorn, England) 
Heater (Hanke, Dieselstrasse, Berlin, Germany) 
Grade A glassware was employed throughout the study. All 
glassware was cleaned either in chromic acid or Decon 75 
concentrate (Atomic Export Import corp. (pty) Ltd., Johannesburg, South 
Africa) before being thoroughly rinsed with disti l led and HPLC grade 
water and dried prior to use. 
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2.4 EXPERIMENTAL 
2.4.1 Stock Solution 
Stock 
of the 
solutions of all drugs used were prepared by dissolving 25mg 
appropriate drug sample in acetonitrile and making up to volume 
in a 25ml volumetric flask. Dilutions were made with acetonitrile to 
produce the concentrations required. 
2.4.2 Mobile Phase Preparation 
Mob il e phase was prepared by mix i ng the requ ired amount of buffer 
solution with the required amount of acetonitri leo No correction for 
volume 
phase 
HVLP, 
changes that occured upon mixing were made . 
was deaerated and filtered through a O.45~m membrane 
Millipore Corp, Bedford, Mass ., USA) prior to use. 
The mobile 
fi Her (Type 
Phosphate buffer was prepared by pipetting a specific volume of 
phosphoric acid (depending upon the required molarity) into a 1 litre 
volumetric flask and making up to volume with HPLC-grade water . 
Sodium hydroxide pellets were then added to adjust the buffer to the 
required pH. 
2.4 .3 . Synthesis of Anhydroerythromycin 
Anhydroerythromycin obtained from Abbott Laboratories, North 
Ch i cago, USA was found to be impure . The synthes i s of 
anhydroerythromycin from erythromycin base (obtained from Sigma 
Chemical Company, St . Louis, USA) according to the method 
reported by Wiley et al (125) was undertaken. Initially this 
yi e 1 ded a product wh i ch conta ined anhydroerythromyci nand 
erythromycin enol-ether. The method was repeated, but the 
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erythromycin base was allowed to stand in hydrochloric acid for sixty 
hours to allow complete degradation. A small amount of 
anhydroerythromycin was obtained, in this manner. 
2.4.4 Columns and Mobile Phases 
Numerous columns and mobile phases were investigated in order to 
optimize separation of erythromycin A, erythromycin ethol-ether and 
anhydroerythromycin (see Table 2.1). Preliminary studies were 
performed using ultraviolet detection (see Section 2.4.6.1. ii). Using 
different co lumns, severa 1 mobile phases of phosphate 
buffer/acetonitrile differing only in aqueous/organic ratios were 
investigated. The effect of buffer strength and pH on the 
elution of erythromycin and degradation compounds was examined. In 
addition, using a mobile phase of O.05M phosphate buffer (pH 
6.3}/acetonitrile (35/65), the effect of varying the flow rate 
between 1.0ml/min and 2.0ml/min, on retention characteristics was 
investigated. 
(i) C8 Reverse Phase Column (10~m) 
A 25cm x 3.9mm internal diameter (i.d) column was packed with 
Techsil 10pm octylsilane (C8) material by the method described in 
section 2.4.5. Using this column numerous mobile phases 
varying in aqueous/organic ratio were used. In addition, the 
effect of varying buffer pH (pH range 3,8-6,32) and buffer 
molarity were character i sed (Table 2.1) 
(ii) Licrosorb C8 Reverse Phase Column (7pm) 
A commercially available 25cm x 3.0mm i.d. Lichrosorb column 
packed with octylsilane (C8) material was used . Mobile phases of 
varying aqueous/organic r atios were investigated . 
(iii) £~ Reverse Phase Column (IOVm) 
This was a 25cm x 3.9mm i.d . column packed with Techsil 10um 
octadecyls i lane (CI8) material. 
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(iv) Novapak End-capped Reverse Phase Column 
This commercially available 15cm x 3.9mm i.d. column packed with 
octadecylsilane (C18) material (Novapak, Waters Associates). A 
mobile phase of 0.05M phosphate buffer (pH 6.32)/acetonitrile 
(70/30) was used. 
Table 2.1 Columns and mobile phases used 
COLUMN CH3CN / BUFFER BUFFER BUFFER 
MOLARITY pH 
1. C8 lOpm 40/60 0.05 6.32 
65/35 0.05 6.32 
60/45 0.10 6.32 
60/40 0.10 6.32 
60/35 0.10 6.32 
30/70 0.10 4.44 
35/65 0.10 4.44 
40/60 0.10 4.44 
50/50 0.10 4.44 
60/40 0.10 4.44 
40/65 0.10 3.80 
40/60 0.10 3.80 
2. Lichrosorb RP-8 30/70 0.05 6.32 
7pm 40/60 0.05 6.32 
50/50 0.05 6.32 
3. C18 10pm 40/60 0.05 6.32 
65/35 0.05 6.32 
50/50 0.05 5.00 
65/35 0.05 5.00 
40/60 0.10 5.00 
50/50 0.10 5.00 
65/35 0.10 5.00 
4. Novapack C18 
end-capped 
30/70 0.05 6.32 
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2.4.5 Column Packing 
The columns were packed using the slurry packing method in 
conjunction with an HPLC column packer. 
The empty column was thoroughly rinsed with methanol and dried. The 
column end frits were sonicated in 6N nitric acid for 5 minutes, 
after which they were thoroughly rinsed. Three grams of column packing 
material were weighed out and slurried in 40ml of carbon tetrachloride 
containing 10% methanol and without delay placed in the slurry 
reservoir. One hundred and fifty millilitres of degassed isopropanol was 
pumped through the system at a pressure of 3,5 x 10 3 kPa. Without 
interrupting the flow of solvent the column was inverted, and a 
further 150m 1 of so 1 vent was pumped through the system. The pump was 
shut off and the column allowed to stabilize for 30 minutes. The column 
was removed from the column packer, and checked using a test mixture. 
2.4.6 Detectors 
2.4.6.1 Ultraviolet Detectors 
(i) Hewlett Packard 1040A Diode-Array Detector 
The Hewlett Packard 1040A Diode-Array detector in conjunction 
with an HP85 personal computer, an HP 9121 dual disc drive 
and an HP 7470A X-Y plotter was used to obtain ultraviolet 
spectra of erythromycin A, erythromyc i n enol-ether and 
anhydroerythromycin. The data storage facility allowed post-
run manipulation of chromatograms. 
(ii) pye-Unicam LC-UV Detector 
This variable wavelength detector was operated at a wavelength 
of 200nm at a sensitivity setting of 0.02 absorbance units 
full scale (AUFS). This detector was used to perform 
pre 1 iminary work on column and mobile phase opt imi zat ion 
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since stabilization following mobile phase adjustments occurs 
more rapidly with UV detection than with electrochemical 
detection, which may take many hours to stabilize. 
2.4.6.2 Electrochemical Detectors 
(i) Metrohm Amperometric Electrochemical Detector 
A Metrohm Model 656 electrochemical detector was used in 
conjunction with a Metrohm Model 641 VA current/voltage 
console. The electrode system, which is depicted in 
Fig . 2.2, consists of a glassy carbon working electrode (WE), 
a glassy carbon auxilary electrode (AE), and a silver/silver 
chloride/KCl reference electrode. 
Prior to use the reference electrode must be filled with 3M 
potassium chloride solution. In addition, the WE and AE must 
be polished using a polishing cloth and aluminium oxide paste. 
(ii) Coulochem Coulometric Electrochemical Detector 
The Coulochem Model 5100A was used and consisted of an 
electronic console, an analytical cell and a guard cell. 
The Model 5010 analytical cell included a dual electrode 
containing two porous graphite in-line working electrodes. 
The detector was operated in the single electrode mode using 
only one of the two electrodes or in the screen mode using both 
electrodes. 
The Mode 1 5020 Guard ce 11 cons i sted of a sing 1 e porous 
graphite working electrode. This was placed between the 
solvent delivery system and the injector in the HPLC system 
and operated at a potent i a 1 of + 1. OV. As such the guard ce 11 
electrolysed any contaminants in the mobile phase. 
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Construction of Voltammoqrams 
Hydrodynamic voltammograms were constructed for both detectors. The 
detectors were set at a relatively low voltage of 0.7V and allowed to 
stabilize. Twenty microlitres of erythromycin solution 
(O .OSpg/pl) was injected onto the system . The electrode potential was 
increased, allowed to stabilize and the equivalent amount of 
erythromycin re-injected into the system. 
The peak height measured was converted to nAmps by simple 
proportion. 
2.S RESULTS AND DISCUSSION 
2.S.1 Column and Mobile Phase 
The choice of column and optimum mobile phase was dictated by the need 
to separate erythromyc in, erythromyci n eno l -ether and 
anhydroer ythromycin within a relatively short retention time. 
The necessity of having a buffer component in the mob i le phase for 
the elution of erythromycin from a C18 and C8 column has been reported 
(126, 127). A phosphate buffer was chosen due to its reported column 
eff i ciency (88). 
Preliminary studies performed using a C8 column with ultraviolet 
detection (200nm) found that the retention time of erythromycin and 
erythromycin enol-ether and consequently peak shape and separation 
were affected by numerous factors. Anhydroerythromycin 
showed poor UV absorption (see Section 2.5.2 . 1) 
The mo 1 arity of buffer was found to have a sub stant i a 1 effect on the 
retention time of the compounds. Increasing the molarity of the 
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buffer from D.D5M to D.1M decreased the retention time of 
erythromycin from 10 minutes to 7.5 minutes, and erythromycin enol-
ether from 19.3 minutes to 14.5 minutes. 
Mobile phase pH was also found to affect retention time. As 
prey i ous ly reported (88). the retent ion time decreased wi th 
decreasing pH (Fig 2.4). 
Fig 2.4 Effect of buffer pH on retention of erythromycin and 
erythromycin enol-ether using a C8 column 
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The aqueous/organ i c phase rat i 0 of the mobil e phase played an 
important role in the final choice of mobile phase. Reducing the 
organ ic portion ensured the compounds remained on the column longer 
increasing retention time and hence separation (Fig 2.5) . 
Fig 2.5 
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Effect of buffer/acetonitr i le ratio on retention of 
erythromycin and erythromycin enol-ether using a Cs 
column 
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separation of 
erythromycin enol-ether, 
60 70 
anhydroerythromycin 
further studies on 
mobile phase were carried out 
electrochemical detection. 
from 
choice 
using 
The Novapak end-capped co 1 umn, although ab le to separate 
erythromyc in and its degradat i on products, was unsu itab le due to the 
extremely long retention time of erythromycin enol -ether (Fig 2.6). 
This column was excluded from further studies . Similarly, the 
L ichrosorb Cs column was excluded from further studies due to poor 
peak shape. 
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Fig 2.5 Chromatogram of erythromycin, erythromycin enol-ether 
and anhydroerythromycin using a Novapack C18 column 
m (3) 
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Mobile phase O.05M phosphate buffer {pH 5.32)/acetonitrile (70/30) 
A compari son between the capac ity factors of erythromyc in, its 
degradation products and a few derivatives using a mobile phase of 
O. 05M phosphate buffer {pH 5.3)/acetonitrile (35/55) on a C8 and a C18 
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column is reported in Table 2.2. With judicious choice of mobile phase, 
both the C8 column and the C18 column were seen to resolve 
erythromycin, anhydroerythromycin and erythromycin enol-ether as seen 
in Fig 2. 7 and Fig 2.8 respectively. As such, both columns were 
suitable for use in this study . 
Table 2.2 Capacity factors of erythromycin and various 
degradation products and derivatives 
COMPOUND 
Des-N-methylerythromycin 
Erythromycin 
Anhydroerythromycin 
Erythralosamine 
Erythromycin enol-ether 
C8 COLUMN 
K' 
3.00 
3.75 
4. 75 
4.77 
8.00 
C18 COLUMN 
K' 
2.67 
3.83 
4.83 
5.17 
9.33 
Mobile phase: 0. 5M phosphate buffer (pH 6.3)/CH3CN (35/65) 
Fig 2.7 
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Chromatogram of erythromycin, erythromycin enol-ether 
and anhydroerythromycin using a Techsil C8 10um column 
Mobile phase O.lM phosphate buffer (pH 4.4)/acetonitrile (65/35) 
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Fig 2.8 Chromatogram of erythromycin, erythromycin enol-ether 
and anhydroerythromycin using a Techsil C18_10um column 
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Increasing the flow rate of the mobile phase from l.Oml/min to 
2.0ml/min greatly reduced analysis time (Fig 2.9) . However, due to 
prohibitive back pressures, which would reduce column life, an optimum 
flow rate of 1. 3ml/min was selected. 
Fig 2. 9 
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2.5 . 2 Detectors 
2.5.2.1 Ultraviolet Detectors 
The ultraviolet spectrum of erythromycin is shown in Fig 2.10 . In 
the wave 1 ength range exami ned (194nm-294nm) it can be seen that 
erythromycin only significantly absorbs UV radiation below 215nm with 
maximum UV absorption at 194nm. Anhydroerythromycin has a UV spectrum 
similar to erythromycin, showing a UV maximum at 194nm (Fig 2.11). 
However the u ltravio let spectrum of erythromyc i n eno l-ether 
revealed a UV maximum at 210nm (Fig 2.12). 
Anhydroerythromycin showed very poor UV absorption characteristics 
(119) and a UV spectrum was only obtained following an on-column 
load of 100pg. 
Fig 2.10 Ultraviolet spectrum of erythromycin 
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Fig 2.11 Ultraviolet spectrum of anhydroerythromycin 
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Fig 2.12 Ultraviolet spectrum of erythromycin enol-ether 
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2.5.2.2 Electrochemical Detectors 
Erythromycin has previous ly been ana lysed by electrochemical 
detection in the oxidative mode using a voltage of O.BOY (34, 119, 123). 
In this study only the oxidative mode was used. The voltammograms 
prepared are shown in Fig 2.13. It can be seen that erythromycin 
has a lower half wave potential (O . BOY) at the porous graphite 
electrode than at the glassy carbon electrode (1.15Y). 
For the Metrohm detector, the best compromi se between detector 
response and baseline noise was an electrode potential of 1.10Y. 
For the Coulochem detector operating in the single electrode mode a 
vo ltage of O. 90Y was used. However, when both electrodes were used 
the upstream screening electrode was operated at O.70Y 
downstream electrode at O.90Y. 
and the 
Use of electrochemical detection showed greatly increased sensitivity to 
anhydroerythromycin. 
2.5.2.3 Choice of Detector 
A sensitive reproducible 
erythromycin, erythromycin 
means of detection capable of measuring 
eno l-ether and anhydroerythromyc i n was 
requ ired . Although absolute sens it i vi ty of the compounds was not a 
major concern for the in vitro studies, in order to quantify all 
three compounds s imu ltaneous ly it was necessary that they have 
sensitivities of similar magnitude . As such, although ultraviolet 
detect i on (200nm) of erythromyc in and erythromyc in eno l-ether was 
adequate, due to the low UY absorpt i v ity of anhydroerythromyc in, 
ultraviolet detection was unsuitable . 
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FIG 2.13 Hydrodynamic voltammograms of erythromycin 
(A) Glassy carbon electrode (Metrohm) 
(B) Porous graphite electrode (Coulochem) 
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This lack of sens it ivity of anhydroerythromycin was overcome by the 
use of e lectrochemi ca 1 detect ion. The amperometri c detector, although 
able to detect all three compounds, rapidly lost sensitivity, 
necess itat ing the frequent repo 1 ish i ng of electrodes. An examp le of 
the rapid loss of sensitivity is shown in Fig. 2.14. This rapid 
loss of sensitivity by a glassy 
in the literature (123, 124). 
carbon electrode has been reported 
The amperometric detector was 
therefore not used in subsequent studies. 
(A) 
(1) 
Fig. 2.14 Chromatogram of erythromycin 
(A) Time = 0 hours 
(B) Time = 18 hours later 
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The coulometric detector operated in the oxidative mode was 
therefore adopted for a 11 further stud ies since it pro v i ded a 
suitable means of simultaneously detecting all three compounds. 
the rapid loss of Although the coulometric electrode did not exhibit 
sensitivity seen in the amperometric 
in sensitivity did occur after constant 
with 6N HN03 returned ce 11 s to the 
sensitivity of older cells showed 
cleaning. 
detector, a gradua 1 decrease 
use. Cleaning the electrodes 
original condition. However, 
limited improvement following 
Sudden decreases in sensitivity were observed when new batches of mobile 
phase were introduced. However, by recyc 1 i ng the mobil e phase a 
general increase in sensitivity to a plateau was observed, 
presumab ly due to e 1 imi nat i on of e lectroact ive contami nants by 
the guard ce 11. 
The coulometric detector was also found to provide the necessary 
sensitivity for the analysis of erythromycin in serum and urine at 
concentrations found in humans after the administration of oral 
dosage forms. (vide infra Chapter 4). 
2.5.3 Solvent degassing 
Although the mobile phase was degassed prior to use, an in-line vacuum 
degassing unit was used to ensure a low dissolved gas concentration 
in the mobile phase. 
2. 6. CONCLUSIONS 
An HPLC method using either a Techsil C18 10pm stationary phase with a 
mobile phase of O. IM phosphate buffer (pH 5.0)/acetonitrile (60/40) or 
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a Techsil C8 lOpm stationary phase with a mobile 
phosphate buffer (pH 4. 4) /aceton itri le (65/35) was 
separating erythromycin, erythromycin enol-ether 
erythromycin. 
The Cou lochem cou lometri c detector operated in 
electrode mode at a polarizing voltage of O.90V 
suitable means of detection. 
phase O.1M 
suitable for 
and anhydro-
the single 
provided a 
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CHAPTER 3 
ACID DEGRADATION STUDIES OF ERYTHROMYCIN 
3.1 INTRODUCTION 
Chemical kinetics is concerned with the rates of reactions and the 
mechanisms by which reactions occur (128). The first goal in a kinetic 
investigation is the determination of the rate equation (129). The 
rate equation defines the relationship between the reaction rate and 
the reactant concentrations. 
Zero order reactions are reactions in which the rate is 
unaffected by changes in reactant concentration and therefore the rate 
of change of concentration of the reactant with time is constant, 
KO. (Equation 3. 1) 
-dC = a 
dt 
Equation 3.1 
Integration of this eRuation yields Equation 3.2. 
Ca = Cao - KOt Equati on 3.2 
where Ca = concentration of reactant at any time, t 
Cao = concentration of reactant at time zero 
t = time 
From Equation 3.2 it can be seen that a plot of Ca against time, t, 
wi 11 be linear and the s lope is equal to the zero order rate 
constant, KO . In general however, the rate of a chemical 
reaction is dependent on the concentration of the reactants. For the 
simple f irst order generalized reaction A - - > B, the rate equation 
is defined in Equation 3.3. 
-dC = Kt a Equat ion 3.3 
dt 
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Integration of this equation yields 
Ca = CaOe-Kt 
the exponential Equation 
Equation 3.4 
3.4. 
From Equation 3.4 it can be seen that a plot of ln Ca against, time, 
t, will be linear and the slope is equal to the first order rate 
constant, K. 
The half-life, t 1/2 is defined as the time for the concentration of 
reactant to reach half the initial concentration. In a first order 
reaction the half-life is independent of concentration and can be 
calculated using Equation 3.5. 
tl/2 = 0.693 Equation 3.5 
K 
For the generalized reaction A + C --> D, if the concentration of C 
at time = 0, is much less than the concentration of A, the reaction 
will behave as if it were a first order reaction; it is said to be a 
pseudo-first order reaction. 
Therefore in order to investigate the rate of degradation of a 
reactant using the integral method, the concentration variation of 
the reactant with time must be measured. 
However, if 
available to 
comp 1 i cated in 
a reaction is extremely slow in terms of the time 
study it, or if its kinetic behaviour becomes 
its later stages, it may be preferable to use the 
'initial rates' method. It is then only necessary to monitor the 
initial 10% of the degradation reaction (130). Throughout this 
period of observation, the change in concentration of reactant is then 
assumed to be negligible (Ca approximately equal to CaO) and the 
initial velocity of the reaction 
from the slope of the plot of Ca 
rate constant is subsequently 
Append i x I). 
is a constant. KO is obtained 
against time. The first order 
calculated using Equation 3.6 (see 
It has 
reactant 
product 
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been suggested however, 
concentration with 
with time may provide an 
Equation 3.6 
that instead of monitoring drug 
time, monitoring degradation 
alternative and better approach 
to kinetic studies. Using this method for the generalized reaction A 
--> B, the concentration of product, B, is measured for as long as it 
is necessary to evaluate ldCb) o ,where ('dCb) is the rate of 
\ dt t" dt t" 0 
change of product formed over the initial part of the reaction. The 
first order rate constant, K, is calculated using Equation 3.7. 
A few 
appeared 
reported 
K = ( ~:b 1 t =0 
c 0 
a 
Equation 3.7 
reports on the use of the initial rates method have 
in the literature (10, 130-134). Taylor et al (134) 
good agreement between rate constants obtained by 
measuring parent drug decrease and degradation product increase 
following a study on the degradation of 3,5 diiodoaspirin. A 
further study also showed the use of initial rates method to be a 
reliable means of calculating rate constants for the simple case of 
a drug decomposing irreversibly to a single product (133). 
However, when this method was applied to a more complex tetracycline 
degradation only limited success was achieved (132). A kinetic study 
on the degradation of erythromycin by Atkins et al (10) obtained 
rat e constants using the initial rate method, monitoring both 
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erythromycin disappearance and erythromycin-enol-ether appearance. 
Results obtained using both methods are summarized in Table 3.1. 
Unfortunately, no attempt was made to calculate rate constants using 
the integral method which would have enabled a comparison between 
the integral and the initial rates methods. 
Table 3.1 Rate constants for erythromycin degradation using the 
'inital rates' method 
Buffer pH 10-5K(min-1 )a 
Erythromycin 
disappearance 
0.1 M phosphate 6.5 9.11 
7.0 2.37 
0.1 M phosphate 7.0 6.59 
0.2 M succinate 6.0 81.80 
a Obtained by the initial rates method 
Reproduced from Atkins et al (10). 
Erythromycin A 
6,9-hemiketal 
appearance ' 
6.25 
2.42 
2.74 
36.90 
The rate constant for 
absolute temperature by 
-E A 
K = Ae RT 
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the react i on 
the Arrhenius 
can be empirically related 
equation (Equation 3.8). 
Equation 3.8 
where A = pre-exponential factor 
Ea = activation energy 
R = gas constant 
T = absolute temperature 
to 
From the logarithmic form of the Arrhenius equation (Equation 3.9) 
it can be seen that the activation energy can be calculated from the 
slope of a plot of log K against the reciprocal of the absolute 
temperature. 
log K = log A - EA 
--'-'--
Equation 3.9 
2. 303R T 
The effects of varying acid pH on the degradation rates of both 
erythromycin base and erythromycin stearate, in addition to the 
effect of pH on the hydrolysis rate of esto1ate are presented. An 
investigation on the temperature dependence of erythromycin base 
degradation was also undertaken. 
3.2 PREVIOUS REPORTS ON ERYTHROMYCIN DEGRADATION 
A lthough there are very few reports in the 1 iterature on the 
stability of erythromycin in aqueous solutions, it has been known for 
many years that erythromycin is susceptible to acid 
degradation. The acidic degradation is reported to yield two 
products depending on the conditions of the reaction (7, 9, 10). The 
proposed pathway of degradation appears in Fig. 3.1 (9, 10). 
59 
Fig 3.1 Proposed acid degradation pathway of erythromycin 
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In 1957, Wiley et al (125) reported that very mild acid 
treatment, pH 2.5 for a few minutes or pH 4.0 for severa 1 hours 
resulted in the formation of anhydroerythromycin (III) (Fig. 3.1). 
However Kurath et al (9) reported that treatment of erythromycin 
with glacial acetic acid at room temperature for two hours yields 
erythromycin A 6-9- hemiketal (erythromycin enol-ether) (II) (Fig. 
3.1), whilst further treatment in acid (dilute methanolic 
hydrochloric acid) for one hour yields the 
anhydroerythromycin. A lternat ive ly erythromycin A treated in 
strong acid (hydrochloric acid, pH 2.0, 30 minutes) only yields the 
anhydroerythromycin. 
Although the formation of erythromycin enol-ether and 
anhydroerythromycin occurs at acidic pH values, at pH 8.8 and above 
dihydroerythromycin is the major degradation product (116). 
An early report investigating the effects of both pH and temperature 
on the rates of degradation of erythromycin concluded the pH of 
maximum stability was approximately pH 8.0 and this decreased with 
increasing temperature. A further study on the stability of 
erythromycin found the pH of optimum stability to be between pH 7.0 and 
pH 7.5 (135). Although this latter study was extensive, no details 
of assay method were given. Atkins et al (10). investigating a 
variety of buffer species in the pH range 3.06 - 7.46, and temperature 
and buffer concentration on the rates of erythromycin degradation 
concluded that pH is the critical factor in determining 
erythromycin stability in acidic aqueous solutions. 
Unlike erythromycin base, erythromycin stearate is thought to be acid 
stable, primarily due to its limited acidic solubility. However 
confl icting reports on the acid stabi 1 ity of erythromycin stearate 
have appeared in the literature. Garrod et al (39) claimed 
erythromycin stearate to be acid stable whilst Wade (136) stated 
erythromycin stearate is acid labile. Using microbiological 
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assay techniques Stephens et al (8) 
and Gleeson (51) also reported that 
erythromycin stearate to acid results 
and more recently Boggiano 
in vitro exposure of 
in rapid degradation. 
, Like erythromycin stearate, erythromycin estolate is also 
reported to be acid stable primarily due to its acid insolubility (36, 
51). The estolate which is primarily absorbed from the gastro-
intestinal tract as the propionyl ester is hydrolysed in serum to the 
active base. As such, a few reports on the rate of hydrolysis in 
serum have appeared in the 1 iterature (137). However there is 
little reported on the aqueous hydrolysis of the estolate. 
3.3 MATERIALS AND APPARATUS 
3.3.1 Materials 
As in Section 2.3.1 
3.3.2 High-Performance Liguid Chromatographic System 
The HPLC system used in this study has been previously described 
(section 2.3.2). A C18 10um column and a dual electrode 
electrochemical detector was used. 
3.3.3 Additional Eguipment 
As in Section 2.3.3 
3.4. EXPERIMENTAL 
3.4.1 Stock Solutions 
Stock solutions of erythromycin A were prepared by dissolving 50mg 
of drug sample in acetonitrile and making up to volume in a 10ml 
volumetric flask. Stock solutions of erythromycin enol-ether and 
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anhydroerythromyci n were prepared by d i sso 1 ving 25mg of appropri ate 
drug sample in acetonitrile and making up to volume in a 25ml 
volumetric flask. Dilutions were made with acetonitri le to 
produce the required concentrations. 
3.4.2 Chromatographic Conditions 
HPLC As in Section 2.3.2 
Mobile phase 
Flow rate 
Detection 
Recorder input 
O. lM phosphate buffer (pH 5.0)/acetonitrile (60/40) 
1.3 ml/min 
Coulometric +0.90V 
10mV 
3.4.3 Test Solutions 
The rate of degradation in several solutions was investigated. 
These test solutions were prepared as follows: 
A) Phosphate Buffer Test Solution 
Phosphate buffer test solutions were prepared by pipetting 6.7ml of 
phosphoric acid into a 1 litre volumetric flask and making up to 
volume with HPLC-grade water . The solution was adjusted to the 
required pH using analytical grade sodium hydroxide pellets. 
B) Hydrochloric Acid Test Solution 
Hydrochloric acid test solutions were prepared by diluting 
concentrated hydrochloric acid with HPLC-grade water . 
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3.5 ERYTHROMYCIN BASE 
3.5 . 1 Experimental 
3.5.1.1 Sample Preparation 
Solutions of erythromycin, erythromycin enol-ether and anhydro-
erythromycin were prepared as in Section 3.4.1. 
3.5 . 1.2 Calibration Curves 
Stock so 1 ut ions of erythromyc in, erythromyc i n eno l-ether and 
anhydroerythromycin were diluted to yield four different 
concentrations. Each concentration was assayed in triplicate. The 
linearity of peak height with concentration was established for the 
three compounds. Cal ibration curves were constructed on the days 
samples were assayed. 
3 . 5.1 . 3 Sampling Procedure 
Method A 
The study was initiated by adding 20ml of test 
maintained in a water bath at the required temperature to 
solution 
the pre-
weighed drug sample . The solution was then vortexed for 30 seconds. 
Samples were withdrawn at appropriate times and analysed for 
erythromycin, erythromycin enol-ether 
HPLC. 
Method B 
and anhydroerythromycin by 
The study was initiated by adding 250pl of erythromycin stock 
solution (5.0mg/ml) to 5ml of test solution maintained in a 
waterbath at the requ i red temperature. The test so 1 ut i on was 
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vortexed for 30 seconds. Samples were withdrawn at appropriate times 
and analysed for intact erythromycin by HPLC. 
Where degradation of erythromycin was rapid, time between 
sampling was short. Consequently, there was insufficient time to assay 
the sample before the next sampling time. To overcome this problem it 
was necessary to use a separate reaction mixture for each individual 
exposure time in the reaction solution. In order to ensure that the 
use of different starting samples did not affect the results, five 
samples were assayed for erythromycin immediately after the 
addition of 20ml of test solution to the erythromycin sample 
(method A) and five samples were assayed immediately after the 
addition of 2S0~1 stock solution to Sml of test solution (method B). 
3.5.1.4 Precision 
Within-run preclsl0n was assessed by degrading five erythromycin 
samples (method B) in hydrochloric acid, pH 3.2 for 10 minutes . The 
samples were assayed for intact erythromycin by HPLC. 
3.S.1.S Degradation in Phosphate Buffer Test Solution 
A Erythromycin Powder 
A 11 stud i es were performed in phosphate buffer test so lut ion 
prepared as in Section 3.4.3. The method was carried out as 
reported in Section 3. 5.1.3 (Method A) using 4.7mg erythromycin base 
with all samples maintained at 370C. The degradation was carried in 
duplicate using the following test solutions . 
TEST SOLUTION Q]i 
1 
2 
3 
4 
5 
3.2 
4. 3 
5. 5 
6.5 
7.0 
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B Erythromycin Solution 
A 11 stud ies were performed in phosphate buffer test so 1 ut i on 
prepared as inSect i on 3.4.3. The method was carri ed out as 
reported in Section 3.5.1.3 (method B) with all samples 
maintained at 370 C. The degradation was carried out in duplicate using 
the following test solutions. 
TEST SOLUTIONS Q!i 
1 3.2 
2 
3 
4 
5 
4.3 
5. 5 
6.5 
7.0 
3.5 .1.6 Degradation in Hydrochloric Acid Test Solution 
All studies 
method was 
were performed in hydrochloric acid test solution. 
carried out as in Section 3.5 . 1.3. (method B) 
duplicate, with all samples maintained at 37 0C, using 
fo 11 owi ng test solutions. 
TEST SOLUTIONS Q!i 
1 2.2 
2 2.9 
3 3.2 
3.5.1.7 Effect of Temgerature 
The 
in 
the 
A 11 stud i es were performed in O.lM phosphate buffer, pH 3.0. The 
method was carried out as in Section 3.5.1.3 (method B) with 
samp les rna i nta i ned at constant temperature ina water bath. The 
degradation was carried out in duplicate. 
66 
3.5.1.8 'Initial Rates' Method 
All studies were performed in O.lM phosphate buffer, pH 4.3, pH 5.5 
and pH 7.0. The method was carried out as in section 3.5.1.3 (method 
A) with samples maintained at 370C in a water bath. 
carried out in duplicate. Samples were analysed in 
rate constants ca 1 cu lated by the integra 1 method 
The studies were 
order to compare 
as well as the 
initial rates method using erythromycin decrease and erythromycin 
enol-ether and anhydroerythromycin increase. 
The first order rate constants were calculated from the apparent zero 
order decrease in erythromycin concentration using the 
relationship (129) shown in Equation 3.10 
K = 
r dC a 1 
tdtJ t=o 
C 0 
a 
Equation 3.10 
Similarly, rate constants were also calculated using the increase 
in both erythromyc in eno l -ether and anhydroerythromyc in us i ng 
Equation 3. 11 and Equation 3.12 respectively. 
K = ~ dt . 
C 0 
a 
K = b1 dt . t 
C 0 
a 
.. 
t = 0 
.. 
= 0 
Equation 3.11 
Equation 3.12 
". KEY 
a ERYTHROMYCIN 
b ERYTHROMYCIN ENOL-ETHER 
d ANHYDROERYTHROMYCIN 
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3.5.2 Results 
3.5.2.1 Linearity and Calibration Curves 
Linearity was established for erythromycin, erythromycin enol-ether 
and anhydroerythromycin over the range of concentrations studied. 
Details of the linearity data and the calibration curves for the 
three compounds are shown in Table 3.2 and Fig. 3.2 respectively. 
Table 3.2 Linearity data for erythromycin, erythromycin enol-
ether and anhydroerythromycin 
Compound Slope V-intercept 
Erythromycin 495.600 -0.0246 
Erythromycin enol- 1265.300 -0.522 
ether 
Anhydroerythromycin 424.630 -0.095 
3.5 . 2. 2 Sampling Procedure 
A relative standard deviation for the assay at 
be 4.6% (n=5) and 2.0% (n=5) for method 
respectively. 
Correlation 
Coefficient 
0.9997 
0.9990 
0.9986 
time = 0 was found to 
A and method B 
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Fig 3.2 Cal i bration curves for erythromycin, erythromycin enol -
ether and anhydroerythromycin 
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Although there is a slight variation in drug concentration at time 
zero, the variation is insignificant. As such, where degradation 
was rapid, a separate reaction mixture for each exposure time in 
the reaction was used. In addition, therefore, to the normal 
limitations in experimental assay reproducibility, each result 
contained a slight deviation due to the variation of drug concentration 
at the start of the time period. 
3.5.2.3 Precision 
Using five samples a relative standard deviation for assay 
precision of 3. 4% was obtained. 
3. 5.2.4 Test Solutions 
At all 
decreases 
pH va 1 ues invest i gated the concentrat ion of erythromyc in 
exponentially with time, whilst erythromycin enol-ether shows 
a rapid increase to approximately 10% of the expected value. This 
result is in agreement with that reported by Atkins et a 1 (10). The 
subsequent degradation of erythromycin enol-ether to 
anhydroerythromycin occurs and the concentration of erythromycin 
enol-ether slowly decreases. An example of the relationship 
between the concentration of each of the three species in the 
reaction as a function of time appears in Fig. 3.3. Below pH 5.5 
erythromycin enol-ether and anhydroerythromycin (Fig. 3.4) are formed . 
However, between pH 5.5 and pH 8.0, in addition to the formation of 
erythromyci n eno l-ether and anhydroerythromyci n, a th i rd compound 
forms (Fig. 3.5). At pH 8, erythromycin degrades only to the 
unidentified peak (Fig. 3. 6) Tsuji and Goetz (116) reported that above 
pH 8.8 the major degradat ion product was di hydroerythromyci n. 
Comparing the retention time of this compound with published 
data on dihydroerythromycin suggests that the unidentified peak 
may well be dihydroerythromycin. 
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Fig 3.3 Plot of concentration versus time for erythromycin, 
erythromycin enol-ether and anhydroerythromycin 
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3.5.2.5 Phosphate Buffer Test Solution 
A Erythromycin Powder 
The individual concentration-time data for erythromycin, erythromycin 
enol-ether and anhydroerythromycin are listed in Appendix 2 and the 
curves are depicted in Fig. 3.7. 
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Fig 3.4 Chromatograms of erythromycin degradation below pH 5.5 
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Fig 3.5 Chromatograms of erythromycin degradation at pH 6.5 
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Fig 3.6 Chromatograms of erythromycin degradation at pH 8.0 
{ 1~ ERYTHROMYCIN 2 ERYTHROMYCIN ENOL-ETHER 3 ANHYOROERYTHROMYCIN 
(4) POSSIBLY OIHYOROERYTHROMYCIN 
I 10 MINS I 
(1) 
Time = 0 
>-
u 
w 
...., 
z: 
..... 
I 10 MINS I 
( 4) 
(1) 
. 
(2) (3) 
t-
U 
W 
...., 
z: 
..... 
74 
Logarithmic plots of erythromycin concentration against time 
(Fig . 3.8) yielded straight lines suggesting that the degradation of 
erythromycin is a pseudo-first order process. The observed first 
order rate constants were calculated from the slopes of the straight 
lines obtained. 
B. Erythromycin Solution 
The individual concentration time data are listed in Appendix 3 and the 
curves are depicted in Fig . 3.9. Semi logarithmic plots of 
erythromycin concentration against time are depicted in Fig. 3.10. 
The observed fi rst order rate constants were ca 1 cu 1 ated from the 
slopes of the stra i ght 1 ines obtained and are compared in Tab le 3.3 
with those obtained using erythromycin powder. 
Table 3.3 Rate constants for erythromycin degradation in O.IM 
phosphate buffer 
Rate constant 
pH K(min- l x 10-3)a R 
3.2 33.600 0.999 
4.3 4.530 0.996 
5.5 0.735 0.999 
6.5 0.084 0. 981 
7.0 0.023 0.936 
a rate constant obtained using Method A. 
b rate constant obtained using Method B. 
R correlation coeffic ient 
K(min- l x 10-3) b R 
74.500 0.993 
6. 700 0.986 
0.518 0.999 
0.067 0.996 
0.038 0. 995 
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Semi logarithmic plots of erythromycin concentration 
versus time in O.1M phosphate buffer 
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Fig 3.9 Plots of erythromycin concentration versus time in O.lM 
phosphate buffer 
0.25 O.JO 
pH 3.2 pH 4.3 
0.20 
0 .25 
::; J 
:r: :r: , , 
0.20 <> <> 
:5 0 .15 5 
z z 
0 0 0.\5 
~ ~ 
< 0-10 < 
'" '" ~ ~ 0.10 z z 
w w 
" " z z 0 0.0.5 0 
" " 0 . " 
0.00 0.00 
0 • 10 
'" 
ao 0 10 20 JO 40 '0 
T!ME (N! NS) TIME (N! NS) 
0·25 pH 5.5 0 . 25 pH 6.5 
0.20 0.20 
::; ::; 
:r: :r: , , 
<> <> 5 0.15 5 0.15 
z z 
0 0 
~ ~ 
< 0.10 < 0.10 
'" '" ~ ~ z z 
w w 
" " z z 0 0.05 0 0.05 
" " 
0.00 0.00 
0 1000 2000 JOOO 0 100 200 JOO 400 
TH£: (M!NS) TIME (HOURS) 
0.25 pH 7.0 
0 . 20 
::; 
:r: , 
<> 5 0.15 
z 
0 
~ 
< 0.10 
'" ~ z 
w 
" z 0 0.05 
" 
0.00 
0 t OO 200 400 
TH£: (HOURS) 
1.00 
0 . 50 
::; 
r , 
'" 
0 . 20 ~
z 
0 0 . 10 
... 
< 
'" ... 0.05 z 
'" u z 
0 
u 
0.02 
0.01 
0 
1.00 
O.!O 
::; 
r , 
'" 
0.20 ~
z 
0 0 . 10 
... 
< 
'" ... a.OS z 
"' U 
% 
0 
u 
0.02 
0.01 
0 
1.00 
0.50 
;! 
, 
78 
Fig 3.10 Semi logarithmic plots of erythromycin concentration 
versus time in O.lM phosphate buffer . 
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there is very little difference between 
obta i ned us i ng both methods. 
erythromycin (method B) 
powder (method A). 
However, 
the 
at pH 3.2 
degrades faster 
At this low pH the 
than 
rate 
rate 
the 
the 
of 
degradation is so fast, dissolution of the powder may have become the 
rate limiting factor leading to a slower degradation rate. 
From Table 3.3 and Fig. 3.11 it is evident that erythromycin shows 
increasing stability with 
at approximately pH 7.0. 
increasing pH reaching a maximum stabil ity 
Although extens i ve a 1 ka 1 i ne degradat i on 
studies were not carried out, studies carried out at pH 8.0 indicate 
erythromycin base is susceptible to alkal ine degradation when 
exposed over a 1 engthy peri od . Rate constants obta i ned show good 
agreement with those published in the literature (Table 3.4). 
Fig 3.11 pH-rate profile of erythromycin in O.lM phosphate 
buffer 
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Table 3.4 Comparison of reported rate constants 
Phosphate Buffer pH Temperature Rate constant 
molarity (OC) (mins x 10-5) 
0.1 7.0 31.5 2.S Amer 
0.1 6. 5 37 5.7 Atkins 
0.1 7.0 37 2. 1 
0.1 6.5 37 6. 7 Glew* 
7.0 37 3.S 
* Method B 
3. 5.2 . 6 Hydrochloric Acid Test Solution 
The individual concentration time data are listed in Appendix 4 and the 
curves dep i cted i n Fig . 3. 12 . At all t hree pH values the erythromycin 
was rapidly degraded. At pH 2.2 the degradation was so rapid the rate 
81 
constant could not be calculated. However, the rate constants obtained 
at pH 2.9 and pH 3.2 are 155 .68 x 10-3 and 38 . 46 x 10-3 min- 1 
respectively. 
Fig 3.12 Plots of erythromycin concentration versus time, 
log concentration versus time in hydrochloric acid 
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3.5.2.7 Effect of Temperature 
The individual concentration-time data are listed in Appendix 5 and the 
curves are depi cted in Fig. 3.13. The observed first order rate 
constants were ca lcu lated from the slopes of the stra i ght 1 i nes 
obtained from the plots of log concentration against time (Fig. 
3.14) and are shown in Table 3.5 . A linear Arrhenius plot was 
obtained and is depicted in Fig 3.15. 
Fig 3.13 Plots of erythromycin concentration versus time, in 
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Table 3.5 Rate constants for erythromycin degradation in 0.1M 
phosphate buffer, pH 3. 5, at 230 C, 280 C and 370 C. 
Rate constant 
Temperature K(min- 1 x 10-3) R 
23 16.5 0.999 
28 25.6 0.999 
37 50.7 0.992 
R correlation coefficient 
Fig 3. 15 Arrhenius plot of erythromycin in 0. 1M phosphate 
buffer, pH 3.5 
10.00 
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3.5.2.8 'Initial Rates' Method 
In Table 3.5, the rate constants obtained using the initial rates 
method are compared with those obtained using the integral 
method. Comparab le resu lts were obta i ned us i ng the integra 1 
, I 
method and the initial rates method using erythromycin decrease. 
However sl ight differences were seen when the rate constants for 
degradat ion were ca leu lated us i ng the increase in erythromyc in 
eno l-ether and anhydroerythromyc in . Thi sis presumab ly due to 
errors in detecting the low concentrations of erythromycin enol-ether 
and anhydroerythromycin. 
Table 3.5 Comparison of rate constants calculated using the 
integral and 'initial rates' methods 
pH Rate constant (min- 1 x 10-3) 
Integral method Initial rates method 
I II III 
4.3 4. 530 4.72 2.91 13.5 
5.5 0.735 0.554 0.554 0.995 
7.0 0.023 0.023 0.047 0.047 
I Rate constant calculated using erythromycin decrease 
II Rate constant calculated using erythromycin enol-ether 
increase 
III Rate constant calculated using anhydroerythromycin increase 
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3.6 ERYTHROMYCIN STEARATE 
3.6.1 Experimental 
3.6.1.1 Sample Preparation 
As in Section 3.4.1 
3.6.1.2 Calibration Curves 
As in Section 3. 5.1.2 
3.6.1.3 Degradation in Phosphate Buffer Test Solution 
All studies were performed in aqueous phosphate buffer prepared as in 
Section 3.4.2. The method was carried out as previously reported in 
Section 3.5 .1.3 (method A) using 6. 6mg erythromycin stearate. All 
samples were maintained at 370 C. The degradation was carried out in 
duplicate using the following test solutions. 
Test solution 
1 
2 
3 
3.6.2 Results 
3.6.2.1 Linearity and Calibration 
As in Section 3.5.2.1 . 
Qf! 
3.2 
4.3 
5.5 
3.6.2.2 Phosphate Buffer Test Solution 
The individual concentration-time data 
enol-ether and anhydroerythromycin are 
for erythromycin, erythromycin 
listed in Appendix 6 and the 
:::; 
I: , 
<0 
E 
% 
0 
~ 
< 
'" ~ % 
"' 
" % 
0 
" 
:::; 
I: , 
<0 
E 
% 
0 
~ 
< 
'" ~ % 
"' 
" % 
0 
" 
86 
curves are depicted in Fig. 3.16. The erythromycin stearate 
dissolved (the sum of erythromycin, erythromycin enol-ether and 
anhydroerythromycin was equivalent to the amount of erythromycin base 
at time; 0) and the subsequent erythromycin concentration showed an 
exponential decrease with time. Logarithmic plots of erythromycin 
concentration against time yielded straight lines (Fig. 3.17) 
suggesting a pseudo-first order process. Rate constants obtained are 
shown in Table 3.7. 
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Fig 3.16 Plots of concentration versus time for erythromycin, 
erythromycin enol-ether and anhydroerythromycin in O.lM 
phosphate buffer 
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Fig 3.17 Sem i logarithmic plots of erythromycin concentration 
versus time in O.lM phosphate buffer 
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Table 3.7 Rate constants for erythromyc in stearate degradation in 
O.lM phosphate buffer 
Rate constant 
pH K(min- 1 x 10-3) R 
3.2 18.90 0.995 
4.3 4.15 0.988 
5.5 0.37 0.993 
R correlation coef f icient 
88 
Although rate constants obtained for erythromycin stearate are 
slower than those obtained for erythromycin base powder, the rate of 
degradation did not appear to be significantly decreased by the use 
of the stearate salt . These findings are in agreement with Boggiano 
and Gleeson (51) that erythromycin stearate is in fact very sensitive 
to acid degradation in vitro. 
3.7 ERYTHROMYCIN ESTOLATE 
3.7.1 Experimental 
3.7 . 1.1 Sample Preparation 
Stock solutions of erythromycin estolate were prepared by 
dissolving 25mg of drug sample in acetonitrile and making up to 
volume in a 25.0ml volumetric flask with acetonitrile. Dilutions were 
made with acetonitrile to produce the required 
concentrations. 
Section 3.4.1. 
Other stock solutions were prepared as in 
3.7.1.2 Calibration Curves 
A stock solution of erythromycin estolate was diluted to yield four 
different concentrations. Each concentration was assayed in 
trip 1 i cate. The 1 inearity of peak hei ght with concentrat ion was 
established. 
3. 7. 1.3 Phosphate Buffer Test Solut ion 
All studies were performed i n aqueous phosphate buffer as in Section 
3.5.1 . 3 (method A). Twenty millilitres of test solution ma i ntained at 
89 
370 C in a water bath was added to 6.8mg erythromycin estolate . The 
degradation was carried out using the following test solutions. 
Test solution 1l.!i 
3.7.2 Results 
1 
2 
3 
4 
5 
3.7.2.1 Linearity and Calibration 
3.2 
4.3 
5.5 
6.5 
7.0 
Linearity was established for erythromycin estolate. Details of the 
linearity data and the calibration curve are shown in Fig. 3.18. 
Fig 3. 18 Calibration curve for erythromycin esto l ate 
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3.7.2.2 Phosphate Buffer Test Solution 
At pH 6.5 and 7.0 the erythromycin estolate was rapidly 
hydrolysed to the free base (Fig. 3.19). The concentration-time data 
for erythromycin estolate are listed in Appendix 7 and the curves are 
depicted in Fig . 3.20. 
-
Fig 3.19 Chromatogram of erythromycin estolate hydrolysis 
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Logarithmic plots of erythromycin concentration against 
(Fig. 3.21) yielded straight lines suggest i ng the hydrolysis 
erythromycin estolate is a pseudo-first order process . 
observed f irst order rate constants are shown in Table 3.8. 
Fig 3.21 Semi logarithmic plots of erythromycin estolate 
concentration versus time , in 0. 1M phosphate buffer 
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Table 3.8 Rate constants for erythromycin estolate hydrolysis in 
0.1M phosphate buffer 
Rate constant 
pH K(min -1 x W 3) R 
6.5 2.85 0.994 
7.0 6.30 0.979 
R correlation coefficient 
I 
~ 
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However, as the pH decreased, the rate of hydro lys i s decreased, 
presumably due to the low acid solubility of the estolate 
limiting the exposure of drug to the solution environment. At pH 5.5 
and below, any erythromycin base resulting from dissolution of the 
estolate and subsequent hydrolysis of the propionate to produce the 
free drug moeity, was rapidly degraded to erythromycin enol-ether and 
anhydroerythromycin. Due to difficulty in resolving erythromycin 
estolate and erythromycin enol-ether 
hydrolysis rates at pH 5.5 and below. 
no attempt was made to measure 
1'1'''' 
u:. 
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CHAPTER 4 
CLINICAL TRIALS AND THE DETERMINATION OF ERYTHROMYCIN .ill BIOLOGICAL 
FLUIDS 
4.1 INTRODUCTION 
In vivo trials, using healthy volunteers were conducted to 
compare the bioavailability of erythromycin following the 
administration of a single oral dose equivalent to 500mg 
erythromyc i n base as either erythromyc in stearate (fi 1m coated 
tablet) or erythromycin base (enteric coated pellets in a capsule). 
These trials also enabled further elucidation of the pharmacokinetic 
parameters of erythromycin. 
In order to undertake in vivo trials a suitable method for the 
analysis of erythromycin in human serum and urine was required. 
Until recently, bioavailability data published on erythromycin have 
been derived predominantly from microbiological assay techniques, 
although several HPLC methods using spectrophotometric (5, 114-119, 
138, 139) and more recently, electrochemical (34, 119-121, 123, 124) 
methods of detection have also been published. 
However, for th i s study a recent ly pub 1 i shed HPLC assay deve loped by 
Stubbs et a I (121), which involved a sol id-phase extraction 
procedure fo 11 owed by a simp le phase separat i on step was used. 
Detection was carried out using a dual-electrode electrochemical 
detector in the oxidative screen mode. Prior to use, this method was 
validated and a pilot trial using one volunteer was conducted to check 
the effecti veness of the analytical method . In addition, a comparison 
between mean serum data and pooled serum data, obtained from the 
clinical tr ials, was undertaken. 
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4.2 ANALYSIS OF ERYTHROMYCIN IN SERUM 
4.2.1 Experimental 
4.2.1.1. Sample Preparation 
Twenty five milligrams of erythromycin was dissolved in 50.0ml 
acetonitrile and 0. 5ml of this solution was made up to 50.0ml with 
blank serum. Appropriate dilutions of this solution were then made. 
An internal standard stock solution was prepared by dissolving 20mg 
oleandomycin phosphate in 10ml acetonitrile. The internal 
standard solution (20pg/ml) was then prepared by di luting 1.0ml of 
this stock solution to 100.0ml with acetonitrile. 
4.2.1.2 Chromatographic Conditions 
HPLC System 
Co 1 umn 
Mob il e Phase 
Flow rate 
Temperature 
Detection 
Chart speed 
Recorder input 
As in Section 2.3.2 
Techsil C18 10pm 
0.05M Phosphate buffer (pH6.3)/ 
acetonitrile (35/65) 
1. 3m 1 /mi n 
350C 
Coulometric screen +0.70V 
analytical +0.90V 
2.5mm/min 
10mV 
4.2.1.3 Extraction Procedure 
One millilitre of serum was vortexed for 30 seconds mixed with 100pl 
of the internal standard solution . The sample was then 
deproteinated by the addition of 1.0ml acetonitrile, followed by 
vortexing for 1 minute and centrifugation for 5 minutes at 
1600xg. 
containing 
extraction 
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The supernatant was transferred into a cu lture tube 
5ml water for loading onto a disposable 1.0ml· C18 
column which had been previously washed with 5.0ml 
acetonitrile and 5.0ml water. The extraction column was subsequently 
washed with 20.0ml water and 5.0ml water/acetonitrile (SO/50). Elution 
from the column into tapered collection tubes was carried out using 
two successive SOO.Oul aliquots of O.OSM phosphate buffer (pH 
6.3)/acetonitrile (40/60) under vacuum. The sample was then dried in 
a rotary vacuum centrifuge. The residue in the collection tube was 
reconstituted in 20.0ul water and vortexed for 1 minute. The sample 
was vortexed for a further 1 minute following the addition of 100.0ul 
acetonitrile, centrifuged for 1 minute at 1600xg and 20ul aliquots of 
the top layer were injected onto the column. 
4.2.1.4 Calibration Curves 
The serum stock solution was diluted to yield four different 
concentrations, the stock solution itself providing the fifth 
concentrat ion. Con cent rat ions ranged from O. 25ug/ml to 5.0ug/ml and 
each concentration was assayed in triplicate. The calibration curve was 
constructed by plotting the ratios of peak height of erythromycin to 
that of the internal standard versus the respective erythromycin 
concentrations. A straight line fit of the data was made by least 
squares linear regression analysis. 
4.2 .1.5 Precision 
Within-run precision was assessed by extracting six spiked serum 
samples each at the upper and lower limits of the concentration range 
studied (0.25ug/ml - 5.00ug/ml). 
4.2 . 1.6 Extraction Efficiency 
Three different concentrations of spiked serum samples were 
assayed in triplicate. All samples were extracted as described in 
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section 4.2. 1.3, except that the internal standard was incorporated in 
the final reconstitution and was thus not carried through the 
extraction procedure . 
Standard so lut ions of erythromyci n correspond ing to those extracted 
above were made up in 1.0ml of 0.05M phosphate buffer (pH 
5.3)/acetonitrile (40/50) and taken to dryness in a rotary vacuum 
centrifuge. These samples were reconstituted as for the serum 
samples, with the internal standard included in the 100.0ul 
acetonitrile aliquot . 
To determine the percentage recovery, the ratio obta ined from the serum 
extracts were compared to those resulting from the equivalent 
concentration of standard solutions. 
4.2.2 Results and Discussion 
4.2.2.1 Linearity and Calibration Curve 
Linearity was established for the range of concentrations studied 
(O . 25ug/ml 5.00ug/ml). Details of the linearity data and the 
calibration curves for erythromycin in serum are shown in Fig 4.1 
Chromatograms of a b lank serum extract and a serum extract 
containing erythromycin and internal standard are depicted in Fig 4. 2. 
The retention time of erythromycin was 7.6 minutes and that of the 
internal standard 5. 6 minutes. 
4.2.2 .2 Precision 
Relative standard deviations of 2. 3% (n=6) and 4.3% (n=6) were obtained 
for the within-run precision studies for the upper and lower 
concentrations respectively . 
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Fig 4.1 Calibration curve for erythromycin in serum 
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FIG 4.2 Chromatograms of a blank serum extract (A) and a serum extract following the 
oral administration of erythromycin (8) 
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4.2.2.3 Extraction Efficiency 
Table 4.1 shows that analytical recoveries of erythromycin from 
serum. A mean recovery of 84.7% was obtained. 
Table 4.1 Recovery data for erythromycin in serum 
SERUM PERCENTAGE RECOVERY MEAN (SD) RSD 
CONCENTRATION 
(pg/ml) SAMPLE NUMBER 
1 2 3 
0.50 85.9 89.8 92.3 89.3 (2.6) 2.9% 
1.00 86.3 79.2 86.0 83.8 (3.3) 3.9% 
2.00 78.2 83.0 82.3 81.2 (2.1 ) 2.6% 
Mean Percentage Recovery (n=9) 84.7 (4.4) 5.1% 
4.2.2.4 Sensitivity and Detection 
Under the conditions of this assay and based upon a signal to noise 
ratio of 3, the detection li mit for erythromycin in serum was 
0.10pg/ml. However, the detection limit could be increased by the use 
of a larger sample injection volume. 
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4.3 ANALYSIS OF ERYTHROMYCIN IN URINE 
4.3.1. Experimental 
4.3.1.1 Sample Preparation 
Twenty five milligrams of erythromyc in was dissolved in 10.0ml 
acetonitrile and 1.0ml of this solution was made up to 50.0ml with 
blank urine. 
The internal standard stock solution was prepared by dissolving 20mg 
oleandomyci n phosphate in 10ml acetonitrile. The internal standard 
solution was then prepared by diluting O.5ml of this stock solution to 
20.0ml with acetonitrile. 
4.3 . 1.2 Extraction Procedure 
One millilitre of urine was mixed with 100pl of internal standard 
solution and vortexed. The sample was transferred to a culture tube 
conta in ing 5. Om 1 water . The samp les were then extracted as for the 
serum samples (Section 4.2.1.3). 
4.3.1.3 Calibration Curves 
A calibration curve was constructed, as described for the analysis of 
erythromycin in serum (Section 4.2.1.4), over the concentration range 
of 5.0pg/ml to 50.0pg/ml. 
4.3.1.4 
Within-ru n 
samples 
studied. 
Precision 
precision was assessed by extracting six spiked urine 
each at upper and lower 1 imits of the concentration range 
100 
4.3.1.5 Extraction Efficiency 
The analytical recovery of erythromycin in urine was assessed as for 
serum samples (Section 4.2.1.6). 
4.3.2 Results and Discussion 
4.3.2.1 Linearity and Calibration Curve 
Linearity was established for the range of concentrations studied 
(5.0ug/ml - 50.0ug/ml). Details of the linearity data and the 
calibration curve for erythromycin in urine are shown in Fig 4.3. 
Chromatograms of a blank urine and a urine extract containing 
erythromycin and internal standard are depicted in Fig 4.4. 
Fig 4.3 Calibration curve of erythromycin in urine 
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FIG 4.4 Chromatograms of a blank urine extract (A) and a urine extract following the 
oral administration of erythromycin (B). 
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4.3.2 . 2 Precision 
Relative standard deviation of 2.3% (n=6) and 1.7% (n=6) were obtained 
for the within-run prec ision study for the upper and lower 
concentrations respectively. 
4.3.2.3 Extraction Efficiency 
Table 4.2 shows that analytical recoveries of erythromycin in 
urine. A mean recovery of 82.6%, was obtained. 
Table 4.2 Recovery data for erythromycin in urine 
URINE PERCENTAGE RECOVERY MEAN (SO) RSO 
CONCENTRATION 
(~g/ml) SAMPLE NUMBER 
1 2 3 
5.0 85.5 87.7 79.4 84.2 (3.5) 4.2% 
25.0 79.2 84.4 79.2 80 . 9 (2.5) 3.0% 
Mean Perentage Recovery (n = 6) 82.6 (3.4) 4. 2% 
4.4 PILOT TRIAL 
4.4 . 1 Experimental 
A pilot trial using one volunteer was conducted to check the 
effectiveness of the analytical method to measure serum and urine 
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concentrations of erythromycin base after the oral administration of a 
commercially available erythromycin stearate formulation (equivalent to 
500mg erythromycin base). The volunteer was a healthy male who was a 
non-smoker with no previous history of kidney or liver disease, and 
who infrequent ly partook of a 1 coho 1 i c beverages. The vo 1 unteer 
rece i ved an honorar i urn for part i c i pat i ng in the tri a 1 and adhered to 
the same standard procedures as those described in Section 4.5.1.3. 
The volunteer received two film 
erythromycin stearate (equivalent 
coated tablets each containing 
to 250mg erythromycin base) 
accompanied with 250ml water following an overnight fast. 
Blood samples were withdrawn at 0, 0.25, 0.50, 0. 75, 1.00, 1.25, 1.50, 
2.00, 2.50, 3.00, 4.00" 5.00, 6.00, 10.00, 12.00 and 24.00 hours after 
the ingestion of the medication . Urine samples were collected during 
the time intervals 0-2, 2-4, 4-6, 6-8, 8-10, 10- 12 and 12-24 hours. 
Samples were frozen at -20oC until analysis. 
Serum and uri ne samp 1 es were ana lysed accord i ng to the methods 
described in Section 4.2.1.3 and Section 4.3.1.2 respectively. 
4.4.2 Results and Discussion 
The HPLC method was suitable for the determination of erythromycin in 
serum and urine following a single oral 500mg erythromycin dose. 
The serum concentration-time profile and cumulative urinary 
excretion profile from this study are depicted in Fig 4.5 and Fig 4.6 
respectively. 
The patient achieved a Cmax of 1.71~g/ml at t max of 2.00 hours. The 
analysis of urine samples collected in the pilot study indicated 
only a small percentage (0.9%) of the administered dose was excreted as 
unchanged erythromycin after 24 hours. 
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Fig 4.5 Serum erythromycin concentration-time profile after the 
ingestion of 500mg erythromycin administered as two 
film coated tablets containing erythromycin stearate 
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Fig 4.6 Cumulative urinary excretion profile after the 
ingestion of 500mg erythromycin administered as two 
film coated tablets containing erythromycin stearate 
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4.5 CLINICAL TRIALS 
4.5.1 Experimental 
4.5.1.1. Four Patient Study 
Four healthy non-smoking volunteers participated in the trials. The 
demographic data of the volunteers are summarized in Table 4.3. 
Volunteers were chosen on the basis of physical health and the 
following haematology, blood chemistry and urinalysis tests: 
Haematology 
Blood chemi stry 
Urinalysis 
Haemoglobin, haematocrit, WBC, RBC, platelet count, 
differential count. 
Serum creatinine, serum urea, blood glucose, serum 
bilirubin, serum alkaline phosphatase, SGPT and 
SGOT. 
Specific gravity, bile, pH, protein, glucose, RBC, 
WBC, epithelial cells, granular casts. 
Table 4.3 Demographic data of the volunteers 
NAME CODE AGE MASS HEIGHT SEX 
(YEARS) (Kg) (cm) 
M. Cawood P1 21 84 184 M 
I K. Fletcher P2 23 90 186 M I 
W. Brunyee P3 24 84 183 M 
L. Hilliary P4 23 85 196 M 
MEAN (SO) 22 .8 (1.1) 85.8 (2.5) 187 . 3 (5 .2) 
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Volunteers signed a combined protocol/consent form (Appendix 8) prior 
to each trial. Volunteers were paid an honorarium for participating in 
the trial and adhered to the standard procedures described in section 
4.5.1.3. 
4.5.1.2 Treatments 
A. Test dose 1 (T01) consisted of a single oral dose of two 
capsules each containing 250mg of enteric coated erythromycin 
base pellets. (Erymax Lot Number: 107157) 
B. Test dose 2 (T02) consisted of a single oral dose of two film 
coated erythromycin stearate tablets containing the equivalent of 
250mg erythromycin base. (Erythrocin Lot Number: 96007M4) 
The volunteers received the t reatments as shown in Table 4.4. Trial 
2 wa s carri ed out two weeks after Trial 1. 
Table 4.4 Treatments received by volunteers 
VOLUNTEER 
PI 
P2 
P3 
P4 
4.5.1 . 3 Standard Procedures 
TRIAL 1 
T01 
T02 
T01 
T02 
TRIAL 2 
T02 
T01 
T02 
T01 
All volunteers had to conform to the following restrictions: 
(a) No drugs, including over-the-counter preparations, were allowed 
for at least a week before the trial and for the duration 
of the trial. 
107 
(b) No alcohol was to be consumed for at least 24 hours before the 
trial and for the duration of the trial. 
(c) No food or drink was to be ingested for 10 hours before the start 
of the trial. 
(d) All volunteers were confined to a semi-reclining position for 
the first five hours of the study except during the voiding of 
urine samples. 
A standardized breakfast consisting of three slices of toast, with 
margar i ne and jam, and 250m 1 orange ju i ce was served two and ha 1f 
hours after the start of the trial. A standard lunch consisting 
of chicken, rice and vegetables followed by fresh-fruit salad was 
given to all the volunteers three hours later. 
4.5.1.4 Sampling Schedule 
The sampling schedule used for both Trial 1 and Trial 2 is given in 
Table 4.5. 
4.5.1.5 Collection and Storage of Blood Samples 
An indwelling O.Bmm butterfly catheter (21G, Teruma Corporation, Tokyo, 
Japan) was inserted into a suitable vein in the forearm of each 
volunteer and strapped into position with adhesive tape so as to 
facil itate mobil ity of the arm. Each 10ml blood sample was withdrawn 
from the butterfly through a sterile hypodermic needle (O.Bmm, Promex 
(Pty) Ltd., Bergvlei, South Africa) by syringe aspiration. The 
butterfly was then flushed with 1.5ml of sterile saline solution 
containing heparin (50 iu./ml). Immediately prior to sampling, the 
butterfly was cleared of the heparin solution by the withdrawl of 2ml 
of blood which was discarded. Ten mill i 1 itres of blood was then 
collected using a new syringe and needle. The blood sample was 
transferred into a labelled vacutainer tube which was stoppered and 
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a 1 lowed to stand for 30 mi nutes. The tube was centrifuged at 
3000 r.p.m. and the serum transferred to a labelled vacutainer 
tube. The serum samp 1 es were stored at -20oC, for a max imum of two 
days, until analysis. 
Table 4.5 BLOOD SAMPLING SCHEDULE 
TIME 
o 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
4.0 
5.0 
6.0 
8.0 
10.0 
12.0 
24.0 
Dose administered with 250ml water 
Breakfast - slices of toast with margerine 
and jam, 250ml orange ju ice 
Lunch - 1 piece boiled chicken, rice and 
vegetables, fruit salad, 200 orange juice 
Supper - volunteers choice 
After lunch the volunteers took water as required 
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4.5.1.6. Collection and Storage of urine samples 
The co 11 ect i on of ur i ne samp 1 es was contro 11 ed by the vo 1 unteers 
themse 1 ves, and was, therefore, not subject to the same degree of 
control as the collection of blood samples. 
The urine output was col l ected in a large measuring cyl inder. The 
volume was measured and a 10m l sample was transferred to a labelled 
vacuta i ner tube, the rema i nder of the ur i ne was discarded. 
Urine samples were stored at -20oC until analysis . 
4.5.1.7 Analysis of Serum Samp l es 
Serum samples were brought to room temperature and then mixed on a 
vortex mixer before being analysed. The samples were prepared 
accord i ng to the method descri bed insect i on 4.2.1. 3. Between 
10pl and 20pl of the final reconstituted sample was injected on to 
the column. 
4.5.1.8 Analysis of Urine Samples 
Urine samples were broug ht to room temperature, mixed using a 
vortex mi xer and ana lysed, accord i ng to the method descri bed in 
Section 4.3.1.2 . 
4.5.1.9 Pooled Serum 
Using the serum samples collected following TD1 administration, pooled 
serum samp les, at each samp 1 i ng time were obta i ned by mi xing 
250u 1 serum from each vo 1 unteer. These 1ml serum samp les were 
vortexed and prepared for injection according to the method 
described in Section 4 . 2.1.3. 
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4.5.2 Results and Discussion 
Four healthy vo lunteers, mean age 22.8 ~ 1.1 years, weighing 85.8 ~ 
2.5kg and of 187.3 ~ 5.2cm average he ight, participated in the 
clinical study. The same volunteers participated in both trials 
ensuring that all four volunteers took both preparations. 
Erythromycin base and erythromycin stearate appeared to be well 
to lerated by the vo 1 unteers for the durat i on of the tri a 1. Gastr i c 
discomfort did however occur in some of the vo l unteers following 
dosing, although this effect was mild and transient. 
The use of an indwelling catheter for the collection of blood samples 
was found to be convenient. However, in one subject (P2) the 
butterfly became blocked. The de lay caused by the remova 1 and 
subsequent replacement of the butterfly resulted in omission of the 
blood samp 1 e schedu 1 ed to be drawn from P2 at 2 hours 30 minutes 
following T02 administration. 
The individual serum concentration-time and urinary excretion data 
following administration of TOI and T02 are listed in Appendices 9 and 
10 and the curves are depicted in Figs. 4.7 - 4.10. 
Mean serum concentration-time profiles and mean urinary excretion 
profiles are shown in Fig. 4.11 and Fig. 4.12 respectively. 
These results show peak blood concentrations following T01 
administration ranged between 1.69 ~g/m l and 2.96 pg/ml, whilst 
those obta i ned fo 11 owi ng T02 admi ni strat i on ranged between 0.77 
pg/ml and 1. 89 pg/m 1. All vo 1 unteers ach i eved a greater Cmax 
following T01 administration than T02 administration. However, due 
to the omitted samp le, it is unknown whether P2 ach i eved a higher 
concentration following T02 administration than the concentration 
reported at 3.0 hours. The average time to reach Cmax is 3.1 ~ 0.54 
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hours and 2.87 .:t 1.1 hours following administration of T01 and T02 
respectively. However, following 
rapid absorption showing a Cmax at 
T02 adminstration P1 exhibited a 
1 hour 30 minutes. All the 
vo 1 unteers exhi bited an absorpt ion 1 ag-t ime of one hour or more 
following both T01 and T02 administration. The lag-time following T02 
administration however, appeared to be more erratic, with two 
volunteers (P3 and P4) only showing detectable amounts of drug after 
two hours. 
It is well 
exposure to 
erythromycin 
known that erythromyc i n base absorpt ion 
acidic gastric fluids. Both the 
stearate and the formulation of 
is impaired by 
preparation of 
enteric coated 
erythromycin base dosage forms have attempted to reduce the gastric 
degradation and hence improve absorption and clinical efficacy. 
Results from the clinical trials carried out reveal, on average, the 
erythromycin base formulation produces higher serum concentrations than 
the erythromycin stearate formulation. The time to reach maximum serum 
concentration was however, similar following the administration of both 
preparations. 
Reports in the literature (8, 51) and acid stability studies carried 
out in our laboratory suggest erythromycin stearate is acid labile. As 
such the lower erythromycin serum levels following administration of 
the erythromycin stearate formulation may be related to acid 
degradation of the erythromycin in the stomach. If the fi 1m coated 
erythromycin stearate tablet remained in the acid stomach for a period 
of time, the film coat will dissolve and expose the' erythromycin 
stearate. The acid-labi le erythromycin stearate would therefore be 
subject to acid degradation in the stomach leading to reduced 
biovailability. Alternatively, if the capsule of the erythromycin base 
formulation releases the pellets in the stomach, the enteric coating 
will still protect the erythromycin base until the pellets pass through 
the pyloric sphincter, prior to absorption. 
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Serum concentration-time profiles following administration 
of test dose I (TOI) 
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Serum concentration-time profiles following administration 
of test dose 2 (T02) 
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Cumulative urinary 
admi nistration of test 
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Cumulative urinary 
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Fig 4.11 Mean serum concentration-time profiles following 
administration of test dose 1 and test dose 2 
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Fig 4.12 Mean urinary excretion profiles following 
administration of test dose 1 and test dose 2 
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In addition, pellets pass through the pyloric sphincter easier than 
tablets which may remain in the stomach and therefore be exposed to the 
gastric fluids for a longer period of time . The erythromycin stearate 
tablets remaining in the stomach may have resulted in increased 
erythromycin stearate degradation, reducing serum concentration, and may 
also be responsible for the erratic lag time following administration 
of erythromycin stearate. 
The results from the cl inical trials are in agreement with several 
reports in the literature (55, 56, 140), that higher erythromycin serum 
concentrations and more regular absorption is obtained following 
administration of a capsule containing enteric coated erythromycin base 
pellets than from a film coated erythromycin stearate formulation. 
Cumulative urinary excretion profiles indicate that a small but 
variable percentage of the administered dose was excreted as 
unchanged erythromycin after 24 hours. The mean percentage of 
original drug excreted unchanged in the urine is 3.38% and 2.69% 
following T01 and T02 administration respectively. No evidence of 
linearity was observed between the total amount of drug excreted 
and the area under the curve (vide infra Chapter 5). Urine samples 
collected during the later stages of the trials contained varying 
amounts of degradat i on products/metabo 1 ites i nd i cat i ng that not all 
the drug is excreted as intact base. 
The i nd i vi dua 1 serum concentrat i on-t ime data from the poo 1 ed serum 
samples are given in Appendix 11. From Fig. 4.13 it can be seen that 
the poo 1 ed serum samp les resu lted ins imi 1 ar concentrat ions to those 
obtained by analysing the samples individually and calculating the 
mean concentrations. Use of pooled samples would greatly reduce 
analytica l costs and time. However, results obtained would be limited 
and would not reveal any large inter-individual variations. 
Fig 4.13 
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Serum . concentration-time profiles following 
administrat i on of test dose 1 - mean and pooled data 
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the HPLC method was effective for the determination of 
base in serum and urine . Data obtained following the 
clinical trials revealed higher serum concentrations of 
erythromycin base were obtained following TD1 administration than 
following TD2 administration. The small and variable amounts of 
base e 1 imi nated in the uri ne and the poor correlation between 
serum and urine concentration suggests that erythromycin urinary 
excretion data are of little value in pharmacokinetic studies . 
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CHAPTER 5 
PHARMACOKINETICS AND COMPARATIVE BIOAVAILABILITY OF ERYTHROMYCIN 
5.1 INTRODUCTION 
The purpose of pharmacokinetics is to study the time course of drug and 
metabolite concentrations in biological fluids, tissue and excreta, and 
to construct suitable models to interpret such data (141). 
Traditionally, pharmacokinetic analysis has involved the use of a 
'compartmentalized' system, with the behaviour of a drug in a 
biological system described in terms of either a one, two or 
multicompartmental model (142). This method, based upon linear 
processes, uses a ser i es of differenti a 1 equat ions to descri be the 
transfer of drug between compartments. Numerous reports on 
compartmenta 1 ana lys is, as we 11 as computer programs ava il ab 1 e for 
optimization of pharmacokinetic parameters have appeared in the 
literature (142-146). 
More recently, however, there has been a move away from compartmental 
ana lys i s and curve f i tt ing towards noncompartmenta 1 and mode 1 
independent approaches (147-149). These methods may be appl ied to 
virtually all linear systems since no assumption of any specific 
compartment model is made. 
Bioavailability is defined as the rate and the extent to which a drug 
becomes available in the systemic circulation (142). Peak serum 
concentrat ion (Cmax ) and time to peak (tmax ). wh i ch can be obta i ned 
directly from the serum concentration-time profile give a rough 
indication of the rate of absorption (150), while the extent of 
absorption can be obtained from the area under the curve (AUC). 
Severa 1 methods however, have been deve loped to Quant ify the rate of 
absorption in terms of a constant, Ka (147-155). An estimate of the 
absorption rate constant, Ka, can be obtained by 'feathering' the curve 
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(142) and subsequent computer-fitting of the serum concentration versus 
time profile, or from the Wagner-Nelson method (153), or various other 
such techniques (143, 149). An alternative method, dependent only on 
the time course of the drug was described in 1978 by Yamoaka (147) and 
Cutler (151). This noncompartmental method has been extensively 
reviewed by Riegelman and Collier (152). This method of statistical 
moments assumes that irrespective of the route of drug administration, 
the zero and first moments are calculated as follows: 
AUC = [C.dt 
o 
MRT =1 t.C.dt 
o 
fC .dt 
o 
= AUMC 
AUC 
Equation 5.1 
Equation 5.2 
where AUC, the zero moment, is the area under the curve, AUMC, is the 
area under the moment curve, and MRT, the first moment, is the mean 
residence time. The use of statistical moments has found widespread 
application in comparative bioavailability studies. 
As previously discussed in Section 1.5 various pharmacokinetic models 
for erythromycin have been reported in the literature . However, 
fo 11 owing admi n i strat i on of either erythromyc i n base or erythromyc i n 
stearate, pharmacok i net i cs of erythromyc i n are best descri bed by an 
open one compartment body model, with absorption described as either 
zero order, first order or as a variable first order process (7,47, 
55, 56, 58, 80, 120). 
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Conflicting reports on the bioavailability of erythromycin following 
administration of erythromycin base and erythromycin stearate have 
appeared in the 1 iterature. Severa 1 reports (37, 46, 56, 80, 140) 
indicate that enteric coated pellets produce higher Cmax and AUC values 
than film coated stearate tablets . However, Clayton et al (48) and 
Malmborg (35) reported erythromycin stear~te tablets to have a greater 
bioavailability than enteric coated pellets. 
In this study, both model-independent and compartmental models were 
used for the pharmacokinetic analysis of the erythromycin serum 
concentration-time data. 
5.2 METHODS OF CLINICAL TRIAL DATA ANALYSIS 
5.2.1 Model-Independent Analysis 
The parameters Cmax and t max were obtained directly from the individual 
serum concentration-time data . The elimination rate constant, Ke , was 
calculated from the terminal slope of the semi logarithmic plot of serum 
concentration versus time, whilst the AUC values from time zero to 
infinity were calculated by the log- linear trapezoidal method. 
Extrapolation to infinity involved the addition of the residual area, 
given by dividing the final measured serum concentration by Ke . 
The mean residence time (MRT) was calculated using Equation 5.2. The 
clin ical trial data were then analysed by the manual feathering of the 
semi logarithmi c p lots of serum con cent rat ion versus time to ca 1 cu late 
Ka . In addition Ka was calculated from the construction of percentage 
drug absorbed versus t ime plots as described by Wagner (153). 
5.2.2 One Compartment Model - First Order Absorption (Model I) 
Absorption of drug is described by a constant input function which is 
independant of the amount of drug present at the site of absorption. 
Drug elimination is assumed to be first order. 
• 
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The following equation (120) was used to characterize this model: 
= Equation 5.3 
dt V 
dC = rate of change of drug concentration in the central 
dt compartment 
Ka = first order absorption rate constant 
D = dose of the drug 
V = volume of central compartment 
Ke = elimination rate constant 
C1 = concentration in the central compartment 
5.2.3 Two Compartment Model - First Order Absorption (Model II) 
The two compartment model attempts to characterize drug concentrations 
if the drug does not rapidly distribute throughout the body. This model 
allows for a distribution phase during which the drug distributes 
between the central compartment and a peripheral compartment. The 
model utilized in this study assumes drug elimination occurs only from 
the central compartment . The differential equation describing the rate 
of change of drug in the periphera 1 and centra 1 compartments are as 
follows (120): 
dC = KaDe-ka(t- tl ag ) 
dt V 
+ K21A2 - K12C1 - KeC1 
V 
Equation 5.4 
K12 = first order rate constant for transfer of drug from the 
central compartment to the peripheral compartment 
K21 = first order rate constant for transfer of drug from 
peripheral compartment to central compartment 
A2 = amount in the peripheral compartment 
Ke = first order rate constant for elimination of drug from 
central compartment. 
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5.2.5 Computer Analysis 
An integrated program PEELFIT (145) operated on an Apple lIe 
microcomputer was used to computer fit the experimental data to Model I 
and Model II. PEELFIT does not reqire any initial estimates or limits 
of parameters in order to run the program, and as such estimates of 
the parameters are ca lcu 1 ated without any constra i nt. All the data 
received equal weighting. 
The computer fitting of experimental data to Model I was subsequently 
carried out using the nonlinear regression program FLEXPLEX (156) 
operated on a VAX STATION 2000 computer. Prior to running of the 
programme, initial estimates and limits of all parameters were 
required. Initial estimates for parameters were obtained from 
'feathering' of the curves and from the Wagner - Nelson method. 
During mode 11 ing, the e 1 iminat ion rate constants were constrained at 
the Ke value obtained from 'feathering' the curves, since estimates of 
Ke and Ka were found to converge to the same value if neither parameter 
• 
was constrained. This convergence has been explained by Tse and 
Welling (157), and in order to overcome this, it has been suggested 
that during computer fitting the Ke value be constrained at the value 
obtained for Ke from 'feathering' (47). As with the PEELFIT program all 
data received equal weighting. 
Initially very poor computer fits were obtained, presumably related to 
the long lag - time which was exhibited in all the patients. In order 
to overcome this problem and acheive a better computer fit and 
consequently to give a more accurate estimate of the parameters, it was 
necessary to adapt the model. As such, when the time following the 
administration of the dosage form was less than the lag - time 
calculated from the program, the predicted concentration was maintained 
at 0.0 ug/ml. Using this computer program, the curve fitting continues 
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unti 1 the percentage difference between the last and present sum of 
squares is less than or equal to 0.00001%. 
5.3 RESULTS ANO OISCUSSION 
5.3.1 Model Independent Analysis 
The values of Cmax , t max , AUC, Ke and t1/2obtained from the serum data 
following TOI and TD2 administration are presented in Table 5.1. As 
reported in Section 4.5 .2. peak blood concentrations following T01 
(erythromycin base formulation) administration ranged between 1.69 
pg/ml and 2.96 pg/ml, whilst those obtained following T02 (erythromycin 
stearate formulation) administration ranged between 0. 77 ~g/ml and 1.89 
pg/ml. All volunteers achieved a higher AUC value following TD1 
administration except P2 who showed a slightly greater AUC value 
following T02 administration. 
The e 1 imi nat i on rate constant, Ke , and t 112' were obta i ned from the 
terminal slope of the semi logarithmic plots of · serum concentration, 
versus time. Secondary peaks or 'bumps' in the elimination phase of 
some of the volunteers, possibly due to enterohepatic recycling, made 
it difficult to calculate the e l imination rate constant. 'Bumps' were 
therefore omitted in the calculation of Ke , since it was felt that 
inclusion of these concentrations in the slope would lead to errors in 
the estimation of Ke . Oata points omitted in the calculation of Ke 
include, in P2 following T01 administration, time ~ 10.0 hours, and in 
PI following T02 adminstration, time ~ 4.0 and 8.0 hours. The Ke values 
for these two volunteers were subsequently calculated using fewer 
available data points . 
The semi logarithmic plots of the individual concentration-time data 
shown in Fig. 5.1 and Fig . 5. 2, reveal the decl ine in erythromycin 
concentration to be, in general, monoexponential . The calculated 
elimination rate constants for all volunteers following T01 
administration did not differ to any great extent except for subject 
TEST DOSE 
T01 
T02 
Table 5.1 Model independent pharmacokinetic parameters 
VOLUNTEER PARAMETERS 
(~~x Cm,x AUC k t 1/2 (pg ml) (pg/ml.h) (h~l) (h) 
PI 3.0 2.96 10.07 0.39 1. 79 
P2 2.5 1.69 4.91 0.29 2.39 
P3 4.0 2.85 11.95 0.30 2.31 
P4 3.0 2.92 7.74 0.52 1.33 
MEAN (SO) 3. 1 (0.54) 2.61 (0.52) 8.66 (2 . 63) 0.38 (0.09) 1.95 (0 .43) 
PI 1.5 1.12 2.98 0.26 2.67 
P2 2.0 1.49 5.25 0.33 2.10 
P3 4.0 1.89 6.60 0.37 1.87 
P4 4.0 0. 77 2.34 0.55 1.26 
MEAN (SO) 2.9 (1.1) 1.31 (0 .42) 4.29 (1.72) 0.38 (0.10) 1.97 (0.5) 
I 
.... 
N 
0'> 
Fig 5.1 
10 . 00 PI 
5 . 00 
' ::; 2.00 
"-co 1.00 
1: 
0.!l0 
z 
0 
... 0.20 < 
0: 
... 
z 0.10 
"' 
" z 0.05 0 00 
" 
0.02 
0.01 
0 2 
10.00 P3 
S.oo 
::; 2.00 
"-co 1.00 
1: 
0.50 
z 
0 
0 
... 0.20 < 
0: 
... 
0.10 0
0 z 
"' 
" z 0 . 05 0 
" 
0 . 02 
0.01 
0 2 
127 
Semi logarithmic plots of serum 
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Semi logarithmic plots of serum concentration versus 
time following administration of test dose 2 
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P4, who displayed a larger Ke and consequently a shorter t1/2' This 
pattern was repeated fol lowing T02 administration suggesting that due 
to intra-individual variation, P4 el iminates erythromycin faster than 
the other volunteers. The faster el imination rate of P4 is however 
unlikely to be the sole factor contributing to the low Cmax and AUC 
following T02 administration, since following T01 administration, the 
Ke value was the same, although significantly higher Cmax and AUC were 
obtained. Excluding the Ke value of P4, the above results revea l both 
low intra- and inter-personal variability in Ke. These results are in 
agreement with Austin et al (58), Jossefsson et al (55) and more 
recent ly T jandramaga et a 1 (140) who a 1 so reported low i nterpersona 1 
variation in Ke values. These reports all suggest that variations in 
serum concentration and AUC values are due to variability in the 
absorption process. 
Results from the statistical moment analysis are shown in Table 5.2. 
Although the use of statistical moments has found widespread 
application in comparative bioavailability studies, results of little 
significance were obtained using this method, with similar values being 
obtained for T01 and T02. The slightly shorter transit time found for 
P4 following administration of both dosage forms is possibly explained 
in terms of the greater elimination rate value for that volunteer. 
Table 5. 2 Relative bioavailab i lity of test dose 1 with respect to 
test dose 2 
MRT (h) 
VOLUNTEER T01 T02 
P1 4.78 5.26 
P2 5.06 4.82 
P3 6.25 5. 78 
P4 4.34 4.74 
MEAN (SO) 5. 10 (0.71) 5.51 (0.41) 
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5.3.2 Computer Analysis 
Observed and calculated serum concentrations obtained by computer 
fitting of data to Model I are reported in Appendix 12. 
Model I appeared to fit the data adequately, provided the predicted 
concentration was constrained at O.Oug/ml, when the time following 
dosage form administration was less than the lag-time predicted by the 
model. Constraining the model to incorporate the lag-time ensured the 
estimates of Ka were a better reflection of the absorption rate 
constant than if the model was not constrained, and the rate constant 
was subsequently calculated as a combination of the lag-time and the 
absorption rate. Results of computer fitting using Model I are 
graphically represented in Fig. 5.3 and Fig. 5.4. The above results are 
in agreement with reports in the literature that suggest erythromycin 
shows first order absorption (7,55,56,80). 
Using PEElFIT, however, neither Model I nor Model II appeared to fit 
the data adequately. Unlike FlEXPlEX, PEElFIT does not requ ire any 
initial estimates or limits on parameters. In addition, the elimination 
rate constant cannot be constrained and the model could not be adapted 
to accomodate the long lag-time, consequently serum concentration-
time profiles correlated extremely poorly with experimental data. 
Results of computer fitting using Model I obtained from PEElFIT are 
shown graphically in Fig. 5.5 and Fig. 5.6. 
From Table 5.3 results of the Ka and Ke values obtained from Model I 
are shown. These values are compared with those obtained using 
PEElFIT, as well as ' feathering' the curve and the Wagner-Ne lson 
method. 
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Table 5.3 Comparison of ka and ke values 
~EST VOLUNTEER MODEL I Hodel I Values obtained Wagner-Nelson 
DoSE Ke Peelfit by curve method 
constrained stripping 
Ka Ke Ka Ke Ka Ke Ka 
WI PI 3.36 0.38 0.38 0.32 0.62 0.38 2.27 
P2 3.10 0.30 0.55 0.30 2.42 0.29 2.86 
P3 1.13 0.32 0.28 0.24 1.89 0.30 1.09 
P4 0.97 0.53 0.36 0.32 0.66 0.53 1.73 
MEAN 2. 14 0.38 0.39 0.30 1.40 0.38 1.49 
W2 PI 3.09 0.28 0.84 0.39 3.40 0.33 
-
P2 4.41 0.34 0.42 0.36 0.63 0. 31 2. 23 
P3 1.30 0.38 0. 29 0.24 1.02 0.38 1.84 
P4 0.79 0.56 0.38 0.33 0.92 0.51 0.64 
MEAN 2.39 0.39 0.64 0.33 1.49 0.38 1.24 
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Comparison of observed and 
serum concentrations following 
dose 1 
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Comparison of observed and 
serum concentrations following 
dose 2 
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Comparison of observed and predicted 
erythromycin serum concentrations 
administration of test dose 1 
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Comparison of observed and predicted 
erythromycin serum concentrations 
administration of test dose 2 
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As can be seen from Table 5.3 the absorption rate constants show great 
intra-persona 1 vari ab i 1 ity and differ dramat i ca lly depend i ng on the 
method of calculation, a factor which must be borne in mind when 
comparing data with other literature reports. However, the estimated 
Ka values obtained can be used to give some indication of the 
relative absorption rates during comparative bioavailabiity studies, 
provided the Ka values are obtained using the same method. Oue to the 
rapid absorption and erratic profile in PI following the administration 
of T02, no estimate for Ka was obtained using the Wagner - Nelson 
method for th i s vo lunteer. Resu lts from PEELFIT revea 1 that mean Ka 
values of 0.39 h- 1 and 0.64 h-1 were obtained following TOI and T02 
administration respectively. However, if the high Ka value of PI 
following T02 administration was omitted, the mean Ka value decreased 
to 0.36 h-1. Computer fitting the data using FLEXPLEX reveal mean Ka 
values of 2.14 h-1 and 2.39 h-1 following TOI and TD2 administration 
respectively whilst from the Wagner - Nelson method mean Ka values of 
1.49 h-1 and 1.24 h-1 were obtained. 
In general, however, the mean Ka values obtained using the same method, 
following TOI and T02 administration did not appear to be significantly 
different, irrespective of the method of calculation . 
Erythromycin concentrations following single dose administration can 
thus be adequately described by an open one compartmental model with 
first order absorption and linear elimination. Following the 
administration of both erythromycin base and erythromycin stearate, the 
Ke values obtained for each volunteer did not differ significantly, 
suggesting little intra-volunteer variability. The limited intra-
volunteer variability in elimination rate constants suggests that 
differences in serum levels and AUC values, following administration 
of both test doses may be due to variation in absorption, probably 
related to degradation of the drug in the stomach. 
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5.3.3 Comparative Bioavailability 
The individual AUC values for each test dose were compared in order to 
ascertain the relative bioavailability of T01 to T02. The relative 
bioavailability Frel, was calculated from the ratio of the AUC values 
and is presented in Tab le 5.4. The mean data revea 1 that TOI has a 
greater bioavailability, in terms of the Frel than T02. In two of the 
volunteers,the observed AUC following the administration of the 
erythromycin base formulation is three fold greater than following the 
administration of the erythromycin stearate formulation, although in 
P2, the bioavailability of both dosage forms was similar. 
Table 5.4 Relative bioavailability of test dose 1 with respect to 
test dose 2 
VOLUNTEERS 
PI P2 P3 P4 MEAN (SO) 
Frel 3.38 0.94 1.81 3.31 2. 36 (1.03) 
In summary, the clinical trials carried out in this study revealed, for 
these volunteers, that the enteric coated erythromycin base formulation 
appears to have a greater bioavailability than the film coated stearate 
tablets. 
Three volunteers (PI, P2 and P4) who participated in this study also 
took part in a clinical trial, carried out in our laboratory, during 
which the volunteers each received erythromycin estolate (Ilosone) 
equivalent to 500mg erythromycin base (120). Identical protocols with 
regard to food and exercise, as used in the clinical trials in this 
study, were employed in the erythromycin estolate trial. Using a 
discriminatory assay method capable of assaying both erythromycin base 
and propionate in the serum, the samples collected were ana lysed for 
free erythromycin base (120). 
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Results from the erythromycin estolate trial, as well as results from 
the clinical trials reported in this study are shown graphically in 
Fig. 5.7. 
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formulation resulted in 
erythromycin base (Cmax ) in 
for the erythromycin base 
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it can be seen that the erythromycin base 
the highest concentration of active 
a 11 three vo 1 unteers. The mean AUC va 1 ue 
formulation was greater than the AUC 
following administration of both erythromycin stearate and erythromycin 
estolate. There appeared to be no differences between the three 
formulations with respect to the time to reach maximum serum 
concentrations (Cmax )' However, the elimination rate of erythromycin 
following administration of the estolate product appears to be slower 
(highest t J ) than following administration of the erythromycin base /2 
and erythromycin stearate formulations . This longer elimination rate 
following erythromycin estolate administration, is presumably due to 
the rate limiting in vivo hydrolysis of the propionyl ester, which must 
occur in order to form the active erythromycin base . 
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Table 5.5 Model independent pharmacokinetic parameters follow~ng 
administration of a single dose of 500mg erythromycln 
as enteric coated pellets, stearate tablets or estolate 
tablets 
VOLUNTEERS 
PI P2 P4 MEAN (SD) 
rrnax (JIg/mIl 
Base 2.96 1. 69 2 . 92 2.52 (0.59) 
Stearate 0.12 1.49 0.77 1.13 (0.29) 
Estolate 0.44 0.38 0.34 0.39 (0.04 ) 
AUC (p,g/ml.hl 
Base 10.07 4.91 7.74 7.57 (2.11) 
Stearate 2.98 5 . 25 2.34 3.52 ( 1. 25 ) 
Estolate 3 . 53 3.68 2.29 3.16 (0.63) 
tmax (hl 
Base 3.0 2.5 3.0 2.83 (0.24) 
Stearate 1.5 2.0 4.0 2.50 (1.08) 
Esto1ate 2.5 3.5 4.0 3.33 (0.63) 
~l/PU 
Base 1. 79 2.39 1. 33 1. 84 (0.43) 
Stearate 2.67 2.10 1. 26 2.01 (0.56) 
Estolate 4.07 5.33 1. 82 3.74 (1.45) 
I 
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Formulation of enteric coated erythromycin base preparation and the 
production of erythromycin stearate and erythromycin estolate have 
attempted to reduce gastric degradation, and subsequently to improve 
absorption and clinical efficacy. Results from the clinical trials 
however, indicate in these volunteers, that the bioavailability 
following the administration of enteric coated erythromycin base is 
greater than following the administration of either erythromycin 
stearate or erythromycin estolate. Erythromycin stearate, although 
reported to be acid stable, was found to be acid labile and, as such, 
susceptible to gastric degradation. While the amount of erythromycin 
base available following erythromycin esto1ate administration, is 
contingent not only upon absorption, but also on the in vivo 
hydrolysis to release the active erythromycin base. Results from this 
study suggest that erythromycin base, although acid labile, if 
suitably formulated to allow protection from the gastric acid, may 
result in better therapeutic efficiency following oral 
administration, than either erythromycin stearate or erythromycin 
esto1ate. 
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Appendix 1 Derivatization of initial rates equation 
Equations for zero order and first order degradations are given 
by Equation A1 and Equation A2 respectively. 
Ca = Cao - KOt 
Ca = Caoe-Kt 
Equation A2 may be expanded 
Ca = Cao [1 -~ + 
11 
to yield Equat ion A3 : 
(Kt)2 _ (Kt)~ 
21 31 J 
Equation A1 
Equation A2 
Equation A3 
If Kt is sufficiently small (rate constant very small) Equation 
A3 can be reduced to Equation A4. 
Under these 
first order 
Equation A1 
Cci = 
As such 
the first 
Equation A4 
circumstances (Kt sufficiently small) zero order and 
are practically i ndistinguishable. From 
and Equation A4 it can be seen that 
Cao - KOt = Cao - CaOKt 
KO = CaoK 
order rate constant can subsequently be calculated 
using Equation AS. 
K = Equation AS 
pH 
3.2 
4.3 
, 
I 
5.5 
6.5 
7.0 
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Appendix 2 Acid degradation data - phosphate buffer test 
solution (method A) 
Concentration (mg/ml) 
Erythromycin Erythromycin Anhydro-
Enol Ether erythromycin 
Time (mins) 
5 0.16 0. 01 0.03 
10 0.13 0.02 0.06 
20 0.09 0.03 0.10 
30 0.06 0.03 0.13 
60 0.02 0.02 0.13 
Time (mins) 
0 0.22 0.00 0.00 
5 0.22 <0.01 0.01 
10 0.20 0.01 0.03 
30 0.19 0.02 0.07 
60 0.16 0. 03 0.12 
120 0.12 0.03 0.18 
240 0.07 0.03 0.23 
Time (mins) 
0 0.25 0.00 0.00 
240 0.21 0.02 0.06 
480 0.18 0.02 0.08 
1440 0.09 0.03 0.15 
2880 0.02 0.03 0.18 
Time (hours) 
0 0.26 0. 00 0.00 
6 0.26 0.01 0.01 
24 0. 24 0. 02 0.03 
48 0.20 0.03 0. 07 
72 0.14 0.01 0.09 
Time (hours) 
0 0.27 0.00 0.00 
6 0.26 0.01 0.01 
24 0.26 0.02 0.02 
48 0.25 0.02 0.04 
72 0. 24 0.03 0.05 
Appendix 3 
pH 
3.2 
4.3 
5.5 
6.5 
7.0 
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Acid degradation data - phosphate buffer test 
solution (method B) 
Erythromycin concentration 
(mg/ml) 
Time (mins) 
5 0.16 
10 0.10 
15 0.07 
20 0.05 
Time (mins) 
0 0.27 
5 0.26 
10 0.25 
15 0.24 
30 0.21 
60 0.18 
Time (mins) 
0 0.22 
240 0.19 
480 0.17 
1440 0.11 
2880 0.05 
Time (hours) 
0 0.19 
96 0.12 
195 0.08 
314 0.05 
397 0.04 
Time (hours) 
0 0.21 
96 0.17 
195 0.14 
314 0.10 
387 0. 09 
Appendix 4 
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Acid degradation data - hydrochloric acid test 
solution 
pH Time (mins) Erythromycin concentration (mg/ml) 
2.2 
2.9 
3.2 
Appendix 5 
Temperature 
(oC) 
23 
28 
37 
o 
5 
10 
15 
20 
o 
5 
10 
15 
20 
o 
5 
10 
15 
20 
30 
0.22 
<0.01 
<0.01 
<0.01 
<0.01 
0.22 
0.10 
0.04 
0.02 
0.01 
0.22 
0.17 
0.15 
0.12 
0.09 
0.07 
Acid degradation data - effect of temperature 
Time (mins) Erythromycin concentration 
(mg/ml) 
0 0. 22 
20 0.16 
40 0.11 
60 0.18 
120 0.03 
0 0.23 
20 0.14 
40 0.08 
60 0.05 
0 0.23 
10 0.13 
20 0.07 
40 0.03 
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Appendix 6 Acid degradation data - phosphate buffer test 
solution (erythroymc in stearate) 
Concentration (mg/ml) 
pH Erythromyc in Erythromycin Anhydro-
Enol Ether erythromycin 
3.2 Time (mins) 
5 0.18 0. 01 0.04 
10 0.15 0.02 0.06 
20 0.10 0.03 0.13 
30 0.06 0.03 0.16 
4.3 Time (mins) 
0 - 0.00 0.00 
10 0.19 <0.01 0.02 
30 0.17 0.01 0.04 
60 0.13 0.02 0. 06 
120 0. 09 0.02 0.10 
5. 5 Time (mins) 
0 0. 23 0.00 0. 00 
480 0.17 0.02 0. 05 
1440 0.08 0.03 0. 15 
2880 0.02 0.03 0. 18 
Appendix 7 
pH 
6. 5 
7.0 
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Acid degradation data - phosphate buffer test 
solution (erythromycin estolate) 
Erythromycin estolate 
concentration (mg/ml) 
Time (mins) 
0 0.27 
20 0.20 
40 0.14 
60 0. 10 
80 0.09 
Time (mins) 
0 0.24 
20 0. 21 
40 0. 19 
60 0.16 
80 0.14 
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Appendix 8 Consent form 
CONSENT TO ACT AS A RESEARCH SUBJECT 
1. Erythromycin i s a macro lide ant ibiot ic used in the treatment of 
many common infections particularly those caused by gram pos iti ve 
organisms. The purpose of this study is to study the 
pharmacokinetics after the administration of two tablets 
conta ining 250 mg of eryth romyc in. 
2. To participate in this trial , I must be in good health on the 
bas i S of an interview and phys ical examination. If I ag ree to be 
a subject, the following will occur. I will begin fasting at 
10.00 pm on the day preceeding the trial. I will arrive at the 
School of Pharmaceutical Sciences at 7.45 am on the day of the 
tria l and a blood sample will be drawn. I will be given two 
tablets each contai ning erythromycin stearate with a 250 ml gl ass 
of water. Blood samples will be drawn at 30 minutes, 1, 1.5 ,2 , 
2.5, 3, 4, 6 , 8, 10, 12, and 24 hours. Urine will be collected at 
o hrs, 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-24 hou r int ervals. I 
will not take any drugs for one week preced ing the t ri al and I 
will follow all dietry inst ructions during the study. 
3. The incidence of untoward effects associ ated wi t h the use of 
erythromycin preparations is l ow. In very rare cases mild gastriC 
i rritation as well as hypersensitivity reactions may occur which 
include fever, eosinophilia and ski n eruptions. 
4. These procedures will have no direct benefit to me but information 
may be obtained concerning erythromycin concentrations in the 
human body. 
5. Thi s information was given to me by Miss F. 
that she will answer any questions I may 
investigat ion . 
Glew . I understa nd 
have concerning this 
6. I wi ll be paid for participation in this study. 
7. Participation in th is study is voluntary. 
refuse to participate or may withdraw at any 
to my standing whatsoever. 
I have t he right to 
time without jeopardy 
NAM E: ................... . SIGNATURE: .... .. .. . . . ... .... .. . 
DATE: ............. . 
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Appendix 9 Serum data - test dose 1 and test dose 2 
TEST DOSE 1 
CONCENTRATION OF ERYTHROMYCIN IN SERUM (ug/m 1) 
TIME 
HOURS P1 P2 P3 P4 MEAN (SD) 
0 0.00 0. 00 0.00 0.00 0.00 
0.05 0.00 0.00 0.00 0.00 0.00 
1.0 0.04 0.00 0.09 0.22 0.09 (0.08) 
1.5 0.04 0. 38 0. 11 0.41 0.24 (0.16) 
2.0 0.62 1.39 0.28 0. 49 0. 70 (0.42) 
2.5 2.86 1.69 0. 39 0.73 1.42 (0 . 96) 
3. 0 2. 96 1. 50 2.10 2.92 2.37 (0 . 61) 
14. 0 2.24 0. 93 2. 85 2. 10 2.03 (0 . 69) 
5.0 1.25 0.56 1.83 1. 59 1. 31 (0.48 ) 
6. 0 0.93 0.36 1.30 0.57 0.79 (0 . 36) 
8 . 0 0.37 0.11 0.94 0.23 0.41 (0.32) 
10 .0 0.21 0. 35 0.40 0.04 0. 25 (0 . 14) 
12 . 0 0.00 0.00 0.00 0.00 0.00 
24.0 0.00 0.00 0.00 0.00 0.00 
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TEST DOSE 2 
CONCENTRATION OF ERYTHROMYCIN IN SERUM 
(ug/ml) 
TIME 
HOURS P1 P2 P3 P4 MEAN (SD) 
O. 0.00 0.00 0. 00 0.00 0.00 
0.5 0.00 0.00 0. 00 0.00 0. 00 
1.0 0.21 0. 09 0.00 0.00 0. 08 (0 .09) 
1.5 1.12 0.14 0.00 0.00 0.32 (0.47) 
2.0 1.06 0. 49 0.22 0.54 0.83 (0.48) 
2.5 0.69 - 0.34 0.56 0. 53 (0 . 14) 
3.0 0. 61 1.16 1.16 0. 70 0.91 (0.25) 
4.0 0.16 0.87 1.89 0.77 0.92 (0.62) 
5.0 0. 20 0.69 1.26 0.41 0. 64 (0 .40) 
6.0 0. 19 0.46 0.93 0.31 0.47 (0 . 28) 
I 8.0 0.36 0. 20 0.31 0.08 0.24 (0.11) 
10.0 0. 08 0.00 0.24 0.00 0.08 (0.09) 
12 .0 0.00 0.00 0.00 0.00 0.00 
24 .0 0. 00 0. 00 0. 00 0. 00 0.00 
TEST DOSE 2 
CUMULATIVE AMOUNT OF ERYTHROMYCIN BASE EXCRETED I IN URINE (mg) TIME ! 
(HOURS) 
P1 P2 P3 P4 MEAN (SO) 
o - 2 0 1. 64 0 0 0.41 (0 .7) 
2 - 4 9.21 0.27 0 2.77 (3.7) 
4 - 6 16.38 10.76 0.95 0.21 7.08 (6.8) 
6 - 8 19.43 11.14 4.63 2.43 9.41 (6 .6 ) 
8 - 10 13.81 5.36 3. 56 10.54 (6.4) 
IlO - 12 22.48 16.33 5. 66 4.87 12.33 (7.4) 
22.59 18 .66 7.28 5.24 13.44 (7.4) 12 - 24 
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Appendix 11 Pooled serum data 
CONCENTRATION OF ERYTHROMYCIN 
TIME IN SERUM (ug/ml) 
(HOURS) 
T01 
o. 0.00 
I 
0.5 0.00 I 
1.0 0.00 
1.5 0.03 
2.0 0.73 I 
I 2.5 1. 78 
3.0 2. 45 
4.0 1. 90 
5.0 0. 69 
6.0 0. 68 
8.0 0. 45 
10.0 0. 17 
12.0 0.00 
24 .0 0. 00 
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Appendix 12 Observed versus predicted erythromycin 
concentration following test dose 1 and test 
dose 2 administration 
test does 1 
PI P2 P3 P4 
TIME (H) OBS PRED OBS PRED OBS PRED OBS PRED 
0 0. 00 0. 00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1.0 0.04 0.00 0.00 0.00 0.09 0.00 0.22 0.00 
1.5 0.04 0.00 0.3B 0.37 0.11 0.00 0.41 0. 00 
2.0 0. 62 0.62 1.39 1.48 0.28 0.00 0.49 0.22 
2.5 2.86 2.84 1.69 1.51 0.39 0.52 0.73 1.65 
3.0 2.96 2.99 1.50 1.35 2.10 1.77 2.92 2.17 
4.0 2.24 2.14 0.93 1.00 2.85 2.36 2.10 2.03 
5.0 1.25 1.38 0.56 0.74 1.83 2.06 1.59 1.50 
6.0 0.93 0.88 0.36 0.54 1.30 1.61 0.57 0.97 
8.0 0.37 0.36 0.11 0.29 0.94 0.89 0.23 0.37 
10.0 0.21 0.14 0.35 0.16 0.40 0.47 0.04 0.13 
12 .0 0.00 0.01 0.00 0.17 0.00 0. 25 0.00 0.01 
OBS - Observed 
PREO - Model I - Ke constrained 
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test dose 2 
PI P2 P3 P4 
TIME (H) OBS PREO OBS PREO OBS PREO OBS PREO 
a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1.0 0.21 0.33 0.09 0.00 0.00 0.00 0.00 0. 00 
1.5 1.12 0.95 0.14 0. 14 0.00 0.00 0.00 0.00 
2.0 1.06 0. 96 1.49 1.48 0.22 0. 00 0. 54 0.46 
2.5 0.69 0.87 0.34 0.28 0.56 0.69 
3.0 0. 61 0.76 1.16 1.20 1.16 1.32 0.70 0.72 
4.0 0.16 0.58 0.87 0.86 1.89 1.66 0.77 0.62 
5.0 0.20 0.44 0.69 0.61 1.26 1. 33 0.41 0.44 
6.0 0.19 0.33 0.46 0.43 0.93 0.96 0.31 0.29 
8. 0 0. 36 0.19 0.20 0. 22 0.31 0.45 0.08 0.11 
10 .0 0.08 0.11 0.00 0. 11 0. 24 0.21 0.00 0.01 
12 .0 0. 00 0.01 0.00 0. 01 0.00 0.01 0.00 0.00 
OBS • Observed 
PRED • Model I - Ke constrained 
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